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Staphylococci, in particular Staphylococcus aureus, are the predominant cause of bone infections
worldwide. These infections are painful, debilitating and with the rise in antibiotic-resistant forms,
increasingly difﬁcult to treat. The growth in the number of prosthetic joint replacement procedures also
provides new opportunities for these infections to take hold. Comprehending the mechanisms by which
staphylococci interact with and damage bone is critical to the development of new approaches to meet
this challenge. This review summarises current understanding of the mechanisms by which
staphylococci infect and damage bone. We address the role of the inﬂammatory response to
staphylococcal infection in disrupting the homeostatic balance of bone matrix deposition and
resorption and thereby mediating bone destruction. A number of virulence factors that have been
shown to contribute to bone infection and pathology are discussed, however no single factor has been
deﬁned as being speciﬁc to bone infections. Although traditionally considered an extracellular
pathogen, there is increasing evidence that staphylococci are able to invade host cells, and that an
intracellular lifestyle may facilitate long-term persistence in bone tissue, enabling evasion of
antimicrobials and host immune responses. ‘Small colony variant’ strains, with mutations disabling
the electron transport pathway appear particularly adept at invading and persisting within host cells,
and exhibit enhanced antimicrobial resistance, and may represent a further complication in the
treatment and management of staphylococcal bone disease.
& 2009 Elsevier GmbH. Open access under CC BY-NC-ND license.Introduction
Bacteria of the genus Staphylococcus are the principal causative
agents of two major types of infection affecting bone – septic
arthritis and osteomyelitis, which involve the inﬂammatory
destruction of joint and bone. These infections cause serious
morbidity and are often difﬁcult to manage (Berendt and Byren,
2004). The principal routes of infection for both osteomyelitis and
septic arthritis are either haematogenous, resulting from bacter-
emia; contiguous, when the infection is transmitted from local
tissue; or direct, resulting from inﬁltration of bone, often
following injury, surgery or implantation of a foreign body, such
as joint replacement (Berendt and Byren, 2004; Ciampolini and
Harding, 2000; Goldenberg, 1998; Lazzarini et al., 2004; Lew and
Waldvogel, 2004). Infections may be acute or chronic and affect
native joints, especially the hip and knee, or prosthetic joints, long
bones, vertebrae and almost any other bone. Osteomyelitis of the
foot is particularly common in diabetic patients (Berendt and
Byren, 2004; Nade, 2003).: +44 207 915 1127.
).
 BY-NC-ND license.Septic arthritis is a joint disease typiﬁed by bacterial colonisa-
tion and rapid articular destruction (Levine and Siegel, 2003).
Inﬁltration and growth of bacteria within the synovium results in
inﬂammation with inﬁltration of leukocytes into the joint ﬂuid
(Goldenberg, 1998; Nade, 2003). The production of reactive
oxygen species and host matrix metalloproteinases (MMPs),
lysosomal enzymes and bacterial toxins contribute to the
destruction of cartilage. This starts with degradation of host
proteoglycans followed by collagen breakdown within hours of
infection, and is mediated by polymorphonuclear leukocytes
(Goldenberg, 1998; Nade, 2003; Shirtliff and Mader, 2002; Stott,
2001). The containment of the inﬂammatory process within the
joint results in increasing pressure, which impedes blood and
nutrient supply to the joint exacerbating joint damage and
facilitating destruction of cartilage and the synovium. Permanent
destruction of articular cartilage and subchondral bone can occur
rapidly, within just a few days (Shirtliff and Mader, 2002).
Osteomyelitis describes a range of infections in which bone is
colonized with microorganisms, with associated inﬂammation
and bone destruction. Acute osteomyelitic foci are characterised
by pus-forming inﬂammation at the site of microbial colonisation.
Damage to bone matrix and compression and destruction of
vasculature is also observed as the infection spreads to surround-
ing soft tissues, which can further exacerbate bone necrosis
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bone, known as sequestra, can form which may then detach to
form separate infectious foci which, due to the lack of vasculature,
are protected from immune cells and antibiotics (Lazzarini et al.,
2004; Lew and Waldvogel, 2004). Such areas of dead, infected
tissues that are inaccessible to antimicrobials or the immune
response can lead to chronic persistence of the infection (Lazzarini
et al., 2004).
The incidence of septic arthritis is between 2 and 10 in 100,000
in the general populace but may be as high as 30–70 per 100,000
in rheumatoid arthritis sufferers or recipients of prosthetic joints
(Goldenberg, 1998; Nade, 2003; Stott, 2001) and is more common
in children than adults, and in males rather than females (Levine
and Siegel, 2003). Haematogenous osteomyelitis most frequently
effects children and the elderly (Lew and Waldvogel, 2004) and in
children, the incidence is typically between 1 in 5000 and 1 in
10,000 (Weichert et al., 2008). It has been argued that the
incidence of haematogenous osteomyelitis is decreasing with an
annual fall in childhood cases of 0.185 per 100,000 people
recorded in Glasgow, Scotland between 1970 and 1997 (Blyth
et al., 2001; Lazzarini et al., 2004; Weichert et al., 2008).
Conversely, osteomyelitis resulting from direct infection is
reportedly on the increase (Gillespie, 1990; Lazzarini et al.,
2004). Local spread of infection from contiguous tissue to bone
or direct infection can occur at any age, with foreign body
implants a substantial risk factor (Lew and Waldvogel, 2004). The
presence of an implant is particularly associated with chronic
osteomyelitis, where antibiotic treatment is frequently ineffective,
and removal of the implant and debridement are required
(Ciampolini and Harding, 2000). Relapsing cases of osteomyelitis
with several decades between episodes have been documented,
and there are records of reactivation ﬁfty or even eighty years
after the initial infection (Ciampolini and Harding, 2000; Gallie,
1951; Greer and Rosenberg, 1993; Korovessis et al., 1991).
A broad range of bacterial species have been isolated in cases of
septic arthritis and osteomyelitis. Pathogens cultured from septic
joints include S. aureus, Streptococcus pyogenes, Streptococcus
pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Serratia
marcescens, as well as Salmonella, Neisseria, Aerobacter, and
Bacteroides species (Nade, 2003; Shirtliff and Mader, 2002).
Staphylococcus and Streptococcus spp., Haemophilus inﬂuenzae,
E. coli, P. aeruginosa, Salmonella and Mycobacterium spp. are all
potential causes of osteomyelitis (Bennet and Bennet, 2006;
Lazzarini et al., 2004; Lew and Waldvogel, 1997, 2004). S. aureus is
the most commonly identiﬁed pathogen in both conditions, by a
substantial margin, regardless of type or route of infection
(Ciampolini and Harding, 2000; Goldenberg, 1998; Lew and
Waldvogel, 2004).
Staphylococcus, principally S. aureus, accounts for between 37%
and 67% of septic arthritis isolates in studies from a range of
nations (Al Arfaj, 2008; Dubost et al., 2002; Goldenberg, 1998;
Ryan et al., 1997). Coagulase-negative staphylococci are less
commonly isolated from arthritic joints, representing between
3% and 16% of Staphylococcus cultures (Al Arfaj, 2008; Dubost et
al., 2002; Ryan et al., 1997). Studies of osteomyelitis in several
developed countries over the past decade have identiﬁed S. aureus
in 38% to 67% of culture-positive cases. Coagulase-negative
staphylococci were identiﬁed in 5% to 15% of culture-positive
patients (Arnold et al., 2006; Blyth et al., 2001; Grammatico et al.,
2008; Karwowska et al., 1998). Surveillance data from the Health
Protection Agency on surgical site infections in the U.K. between
1997 and 2005 found S. aureus to be the causative agent in 41.4%
of hip prosthesis, 33.5% of knee prosthesis, 53% of open reduction
of bone fracture and 59.1% of hip hemiarthroplasty infections.
Coagulase-negative staphylococci accounted for 15.1%, 20.7%, 7.5%
and 6.3% of these infections, respectively (U.K. Health ProtectionAgency, 2008). S. epidermidis is the most common coagulase-
negative Staphylococcus species in many types of infection,
including osteomyelitis and infection of prosthetic joints, but
other species, including Staphylococcus simulans, Staphylococcus
hominis, Staphylococcus capitis, Staphylococcus caprae and Staphy-
lococcus lugdunensis have all been reported (Greig and Wood,
2003; Lang et al., 1999; Murdoch et al., 1996; Vallianou et al.,
2008).
Clearly S. aureus, and to a lesser extent other staphylococci, are
pathogens of major importance in skeletal infections. The number
of joint replacement procedures is increasing: 220,000 hip
replacements were performed in the USA in 2003, a 38% rise
from 1996, with numbers projected to rise to 572,000 by 2030.
Total knee replacements reached 418,000 in 2003 and are
expected to undergo a similar rise, especially in light of an aging
population (Lee and Goodman, 2008). In cases of septic arthritis
antibiotic therapy is frequently effective if applied rapidly,
appropriately and in combination with joint drainage (Shirtliff
and Mader, 2002). Osteomyelitis is, however, often refractory to
antibiotic treatment, a problem exacerbated by the increasing
levels of antibiotic resistance amongst Staphylococcus spp. This is
complicated further by the emergence of particularly persistent,
antibiotic-resistant ‘small colony variant’ forms that may be
selected for by certain current treatment regimens (Ciampolini
and Harding, 2000; Henderson and Nair, 2003; von Eiff et al.,
1997a). Staphylococcal bone infections are thus likely to be a
continuing and probably increasing problem, and understanding
of the interaction of these pathogens with bone is central to
development of the novel therapeutic strategies required to treat
increasingly antibiotic-resistant and persistent infections.Genomic features of staphylococci associated with bone
infections
A number of studies have attempted to identify an association
between the possession of certain virulence genes by S. aureus and
invasive disease. Thus Peacock et al. (2002) suggested that the
possession of certain combinations of virulence factor genes is
associated with invasive disease, and increased severity of
infection following examination of a panel of 334 S. aureus
isolates by PCR. The isolates comprised those from 179 healthy
patients, 94 hospital-acquired isolates and 61 community-
acquired isolates. Seven putative virulence genes, including the
adhesin genes fnbA and cna, the toxin genes sej, eta and hlg, and
icaA, which is involved in bioﬁlm production, were found to be
associated with invasive isolates. The association with speciﬁc
types of invasive infection was not examined and indeed the small
number of isolates examined in this study would have precluded
such an analysis (Peacock et al., 2002). The genes for the
ﬁbronectin-binding proteins fnbA and fnbB have been reported
to be present in 98% and 99% of clinical isolates, respectively, from
a range of orthopaedic associated infections, whereas the cna
gene, encoding the collagen-binding protein was identiﬁed in just
46% of isolates (Arciola et al., 2005). Another study by Peacock
et al. (2000) found the prevalence of both fnbA and fnbB genes, as
opposed to just one of the two, to be signiﬁcantly higher in
invasive isolates than in ‘carriage’ strains in a panel of 163 strains,
which included septic arthritis and osteomyelitis isolates. Genes
encoding Panton-Valentine leukocidin were found to be present in
59 of 89 S. aureus isolates from cases of acute haematogenous
osteomyelitis. The presence of pvl genes is associated with an
increased risk of severe infection requiring intensive care,
bacteremia and more severe systemic inﬂammation (Bocchini
et al., 2006; Sdougkos et al., 2007). However, one of the problems
with the above studies is that it is unclear how representative
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establishments and regions across the world, since strain typing
was not reported.
Strain typing studies of S. aureus, using multilocus sequence
typing (MLST) and comparative genomic microarray hybridiza-
tions have so far failed to identify any speciﬁc clonal lineages
associated with invasive disease (Feil et al., 2003; Lindsay et al.,
2006). However, these studies did not use a collection of isolates
from speciﬁc invasive diseases and therefore do not rule out the
possibility that speciﬁc lineages or genes are associated with
speciﬁc types of infection, such as osteomyelitis or septic arthritis.
To date, the only genome comparison study relevant to S. aureus
bone infections has been done using comparative genome
microarray hybridisations of the S. aureus UAMS-1 strain, isolated
from an osteomyelitis patient, with a range of genome sequenced
strains (Cassat et al., 2005). These authors found variations in the
complement of adhesin, toxin, exoenzyme and regulatory genes.
Although it is not possible to draw general conclusions about
association with bone infection from characterisation of a single
strain, the presence of fnbA, but not fnbB or the bone sialoprotein-
binding gene bbp, in UAMS-1 suggest that fnbB and bbp are
dispensable for bone infection, at least in certain genetic back-
grounds. Thus at this juncture there is a lack of evidence to
support or disprove an association between speciﬁc S. aureus
lineages or speciﬁc genomic features and the pathogenesis of
bone infections.Bone as a target organ
In terrestrial vertebrates mature bone is made up of dense
surface plates of bone, known as the cortices, and within these is a
network of bone struts oriented to oppose loading forces, known
as trabecular bone. Trabecular bone is typically replaced every
3–4 years, with the denser cortical bone taking over a decade to
replace in adults (Blair, 1998). This process of continual remodel-
ling is required to remove old bone and microfractures to ensure
bone integrity and mineral homeostasis (Vaananen and Laitala-
Leinonen, 2008). The skeleton is a dynamic organ system, in a
state of perpetual turnover which is continually remodelled by the
actions of two cell types (Henderson and Nair, 2003). Osteoblasts
are responsible for the deposition of bone matrix; they are found
on bone surfaces and are derived from mesenchymal osteopro-
genitor cells. These cells secrete osteoid, a mixture of bone matrix
proteins primarily made up of type I collagen (over 90%),
proteoglycans such as decorin and biglycan, glycoproteins such
as ﬁbronectin, osteonectin and tenascin-C, osteopontin, osteocal-
cin and bone sialoprotein, oriented along stress lines (Blair,
1998; Mackie, 2003). Osteoblasts are also thought to facilitate
the mineralization of bone matrix, whereby hydroxyapatite,
[Ca3(PO4)2]3 Ca[OH]2, crystals form, making up around 90% of
bone matrix (Blair, 1998; Mackie, 2003). It is thought that
‘nucleators’ are required to instigate mineralisation, and phos-
phate-containing matrix proteins like bone sialoprotein and
osteopontin are likely to play such a role (Henderson and Nair,
2003; Mackie, 2003; van de Lest and Vaandrager, 2007).
Osteoblasts also produce tissue non-speciﬁc alkaline phosphatase
(TNAP) which cleaves phosphate esters to liberate free inorganic
phosphate, which is key to the process of mineralisation (van de
Lest and Vaandrager, 2007). Osteoblasts are not terminally differ-
entiated, and some may form osteocytes and become implanted in
the bone matrix, eventually ceasing the secretion of osteoid, whilst
others undergo apoptosis (Blair, 1998; Mackie, 2003). Osteocytes are
also involved in bone maintenance, detecting stress within the bone
through mechanosensitive mechanisms located in extensive cellular
projections, called canaliculi, that interconnect osteocytes (van deLest and Vaandrager, 2007). Osteocytes are thought to respond to
mechanical stress by undergoing apoptosis, leading to osteoclast
recruitment and differentiation, possibly by alterations in the levels
of soluble factors produced by the osteocyte. Candidates include
transforming growth factor b (TGF-b), which may suppress
osteoclastogenesis when produced by healthy osteocytes (Henriksen
et al., 2009; Matsuo and Irie, 2008).
The opposing action of bone matrix removal is performed by
osteoclasts, multinucleate cells that are derived from the macro-
phage-monocyte lineage. These cells express large quantities of a
vacuolar-type H+-ATPase on their cell surface, along with chloride
channel 7 (ClC 7) enabling localised hydrochloric acid secretion
into a closed compartment, known as the resorption lacuna, and
subsequent solubilisation of bone mineral (Blair et al., 1989; Blair,
1998; Kornak et al., 2001; Vaananen and Laitala-Leinonen, 2008).
The cell is attached to the bone matrix by a sealing zone
membrane to create this compartment, and fusion of acidiﬁed
vesicles with the plasma membrane contributes further to acid
release (Vaananen and Laitala-Leinonen, 2008). Following mineral
solubilisation, proteolysis of bone matrix proteins is then possible.
Cathepsin K is centrally involved in degradation of bone matrix, it
is highly expressed by osteoclasts and digests substrates such as
collagen and osteonectin (Bossard et al., 1996; Drake et al., 1996).
Evidence from knock-out mouse and selective inhibitor experi-
ments indicates that cathepsin L, and MMPs also play a role in
degrading bone matrix (Everts et al., 2006). Osteoclasts also
secrete acid phosphatases, such as tartrate-resistant acid phos-
phatase (TRAcP), which is used as an osteoclast marker and is
activated by cathepsin K cleavage (Blair et al., 1989; Blair, 1998;
Ek-Rylander et al., 1991; Ljusberg et al., 2005). TRAcP is able to
generate reactive oxygen species in addition to having phospha-
tase activity (Hayman and Cox, 1994). The exact cellular function
of TRAcP in bone resorption is not well understood, but serum
TRAcP levels correlate with bone-resorptive activity, and TRAcP-
deﬁcient mice exhibit reduced osteoclastic bone resorption and
increased bone mineralization (Angel et al., 2000; Hayman et al.,
1996; Nesbitt and Horton, 1997; Salo et al., 1997).
The balance of activity between these two cell types is crucial
to maintaining the proper homeostasis of bone turnover, and any
shift in the relative levels of osteoblast and osteoclast activity can
result in bone pathology (Henderson and Nair, 2003). Infection
with a pathogen such as S. aureus is capable of stimulating such a
shift, mediated in part by induction of an inﬂammatory response.
There is intimate interaction between the two cell types, with
osteoblasts interpreting the majority of extracellular signals and
subsequently modulating osteoclast differentiation and function
(Henderson and Nair, 2003; Matsuo and Irie, 2008). Interaction
between the RANK (receptor activator for nuclear factor kB)
receptor, expressed by osteoclast precursors, and its cognate
ligand, RANKL, expressed by osteoblasts is essential for osteoclas-
togenesis (Matsuo and Irie, 2008). RANKL is a homotrimeric
protein displayed on the membrane of osteoblasts, although it
may be secreted following cleavage by MMPs 7 or 14, or ADAM (a
disintegrin and metalloprotease domain) (Boyce and Xing, 2008;
Hikita et al., 2006; Lynch et al., 2005). Suppression of MMP 14-
mediated secretion enhances osteoclastogenesis (Boyce and Xing,
2008; Hikita et al., 2006). The RANK receptor is a homotrimeric
transmembrane protein belonging to the tumour necrosis factor
(TNF) receptor superfamily. Following binding of RANKL to RANK,
TRAF (TNF receptor-associated factor) adaptor proteins are
recruited, with binding sites for TRAF2, TRAF5 and TRAF6 all
present on RANK (Kim et al., 1999; Wada et al., 2006). TRAF6
seems to play a central role in RANK-mediated osteoclast
formation, and mice deﬁcient in TRAF6 are osteopetrotic (Lomaga
et al., 1999) whereas TRAF2 and TRAF5 are relatively marginal
players in osteoclastogenesis (Kanazawa et al., 2003; Kanazawa
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activates a number of transcription factors, including NFkB
(nuclear factor k B), AP-1 (activator protein 1) and NFATc1
(nuclear factor of activated T-cells, cytoplasmic, calcineurin-
dependent 1) which drive osteoclast differentiation (Matsuo and
Irie, 2008; Wada et al., 2006). Osteoprotegrin (OPG) is an
endogenous inhibitor of RANKL signalling, functioning as a decoy
receptor that binds to RANKL and prevents its association with
RANK (Wada et al., 2006; Yasuda et al., 1998).Inﬂammation in bone infection
A number of host cytokines play a signiﬁcant role in the
pathogenesis of osteomyelitis, and there is strong evidence that
production of these cytokines is induced by staphylococcal
infection of bone, and that they directly contribute to bone
destruction. In particular, the inﬂammatory cytokines tumour
necrosis factor a (TNFa), interleukin 1 (IL-1) and IL-6 seem to be
especially important in bone physiology and pathology (Kwan
et al., 2004). In patients with acute osteomyelitis, plasma levels of
TNFa, IL-1b (the secreted form of IL-1) and IL-6 are all elevated
(Evans et al., 1998; Klosterhalfen et al., 1996). High levels of IL-1b,
IL-6 and TNFa are also found in the synovial ﬂuid of patients with
septic arthritis (Osiri et al., 1998; Saez-Llorens et al., 1990).
Interestingly, speciﬁc polymorphisms in the IL-1a and IL-6 genes
have recently been found to be associated with an increased risk
of osteomyelitis in the Greek population (Tsezou et al., 2008).
A number of animal models of S. aureus osteomyelitis reveal
that bone infection can lead to elevated levels of these cytokines
both locally and systemically. Increased levels of IL-1b have been
measured in the tibiae of 22-month-old rats experimentally
implanted with S. aureus-infected needles, and the same animals
have increased circulating levels of IL-6 (Garcia-Alvarez et al.,
2009). In a murine osteomyelitis model, bone levels of IL-1b and
IL-6 are signiﬁcantly increased in the early post-infection period,
with TNFa rising later during the infection (Yoshii et al., 2002).
The local source of these cytokines is not fully clear. Production of
IL-1b can be induced in human osteoblast-like cell lines by a
variety of stimuli, including TNFa (Pivirotto et al., 1995). However,
infection of primary mouse osteoblasts with S. aureus results in
increased transcription, but not increased protein synthesis or
secretion of IL-1b (Marriott et al., 2002). TNFa is detectable only
at low levels in human osteoblasts derived from mesenchymal
stem cells and the osteosarcoma cell line MG63 (Bu et al., 2003).
Inﬁltrating immune cells may therefore be a more likely source of
IL-1b and TNFa in bone in response to infection (Bost et al., 1999;
Ishimi et al., 1990; Marriott et al., 2002; Mundy, 1991; Robinson
et al., 2007). IL-6 however, is produced by osteoblasts in response
to a variety of signals, including infection with S. aureus (Bost et
al., 1999; Ishimi et al., 1990).
These cytokines have potent effects on the process of bone
remodelling, and are strongly implicated in the pathology of
osteomyelitis. Cell culture models support the view that IL-1 and
TNFa stimulate the proliferation and differentiation of osteoclast
progenitors into mature osteoclasts in the presence of osteoblasts
(Mundy, 1991; Pfeilschifter et al., 1989; Tokukoda et al., 2001).
TNFa and IL-1b also stimulate osteoclast-mediated bone resorp-
tion, a process which may also require the presence of osteoblasts
(Azuma et al., 2000; Taubman and Kawai, 2001; Thomson et al.,
1987). Similarly, IL-6 increases bone resorption activity and
osteoclast number in cultured mouse calvariae, and stimulates
osteoclast differentiation in the presence of osteoblasts (Ishimi
et al., 1990; Kotake et al., 1996). In vivo, local administration of
IL-1 and TNF antagonists in a non-human primate model of
periodontitis results in signiﬁcant reduction of osteoclast forma-tion and bone destruction (Assuma et al., 1998). Intravenous
administration of TNFa and IL-1 in mice stimulates bone
resorption in a dose-dependent fashion (Konig et al., 1988), and
deletion of the murine IL-1R, TNF-R1 and TNF-R2 receptors and of
caspase-1 signiﬁcantly decreases osteoclast number and the area
of bone resorption in calvariae following lipopolysaccharide (LPS)
injection (Chiang et al., 1999).
IL-1b and TNFa also inhibit the differentiation of mesenchymal
stem cells into osteoblast-like cells, and suppress the accompany-
ing mineralisation and increased expression of alkaline phospha-
tase and procollagen I genes, although only TNFa inhibits
osteonectin and osteopontin gene expression (Lacey et al.,
2008). TNFa also decreases production of type I collagen and
osteocalcin, and of alkaline phosphatase in a variety of osteoblast
cell culture and bone tissue explant models, thereby reducing
matrix deposition and mineralisation (Canalis, 1987; Centrella
et al., 1988; Li and Stashenko, 1992; Nanes et al., 1989, 1991;
Nanes, 2003; Smith et al., 1987).
Surface-associated material (SAM) from S. aureus stimulates
bone resorption and osteoclast formation, and blockade of IL-1 or
TNFa signalling completely abolishes this bone resorption activity.
Neutralisation of TNFa and IL-6 fully abolishes SAM-stimulated
osteoclastogenesis, with antagonism of IL-1 having only a partial
effect (Meghji et al., 1998; Nair et al., 1995). The effect of this SAM
on osteoclast formation and stimulation of resorption does not
require co-culture with osteoblasts, and does not require RANKL
signalling (Lau et al., 2006). S. epidermidis surface material can also
induce bone resorption, by a mechanism that is strongly dependent
on TNFa and, to a lesser extent, IL-1 (Meghji et al., 1997).
Induction and release of these cytokines in response to
pathogen-associated molecules involves two main classes of
pattern recognition receptors (PRRs), the Toll-like receptors (TLRs)
and NOD-like receptors (NLRs). The production of TNFa and IL-6
by murine macrophages in response to S. aureus cell wall
preparations is dependent on TLR2, and TLR2-deﬁcient mice
exhibit reduced survival of intravenous S. aureus infections
compared to wild-type counterparts (Takeuchi et al., 1999,
2000). Signalling through TLRs, in response to microbial ligands
such as LPS, ‘primes’ the cell for IL-1b production by inducing
expression of the inactive, pro-form of the cytokine (Creagh and
O’Neill, 2006; Kahlenberg et al., 2005). IL-1b is synthesised as a
31-kDa precursor molecule, and is processed to produce a 17-kDa
active molecule by caspase-1. Caspase-1 activation, and subse-
quent processing and release of active IL-1b involves assembly of
a multiprotein complex known as the inﬂammasome. This
complex consists of caspase-1, the adaptor protein ASC (apopto-
sis-associated speck-like protein containing a caspase recruitment
domain (CARD)) and one of several NLR proteins, of which four are
known to associate with inﬂammasomes (Ting et al., 2008). Each
NLR responds to different activating signals, and although the
exact recognition steps remain to be elucidated, reported stimuli
include ﬂagellin, anthrax lethal toxin, and muramyl dipeptide
(Boyden and Dietrich, 2006; Faustin et al., 2007; Franchi et al.,
2006; Miao et al., 2006). A broad range of stimuli for NLRP3 (NLR
family pyrin domain containing 3) have been reported, including
S. aureus. Although NLRP3 and ASC are essential for IL-1b
secretion by murine macrophages in response to S. aureus, the
stimulating signal is as yet unknown, and deletion of the a-, b-
and g-toxins does not perturb production of the cytokine
(Mariathasan et al., 2006; Ting et al., 2008). The inﬂammasome
is involved in cell death in response to bacterial invasion (Marriott
et al., 2002; McCall et al., 2008) and although invasion of murine
osteoblasts by S. aureus induces apoptosis, it is not established
whether the inﬂammasome is involved (Tucker et al., 2000).
The major signal transduction events following binding of IL-1
and TNF to their respective receptors are shown in Fig. 1.
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Fig. 1. Schematic diagram of IL-1 and TNF signal transduction events. (A) IL-1 binding to IL-1RI results in recruitment of the IL-1 receptor accessory protein IL-1RAcP, which
form a complex that, via the intracellular Toll/IL-1 receptor (TIR) domains of the two receptor molecules, engages the MyD88 (myeloid differentiation factor 88) adaptor
protein (Arend et al., 2008; Dinarello, 2009; Verstrepen et al., 2008). MyD88 binding initiates phosphorylation of IRAK-4 (interleukin-1 receptor-associated kinase 4), IRAK-
2 and IRAK-1. IRAK-1 recruits TRAF6 and these two proteins localise to the cell membrane where they associate with TAK1 (TGF-b-activated kinase 1), TAB1 (TAK1-binding
protein) and TAB2. The TAK1/TAB1/TAP2/TRAF6 complex translocates to the cytosol where TRAF-6 is poly-ubiquitinated and TAK1 is subsequently phosphorylated, and
activates NF-kB, p38 MAPK and JNK. The MyD88 adaptor molecule and downstream signalling events are common to most Toll-like receptors (TLRs), and, via TRAF6, this
pathway also converges with RANKL signalling. (B) Engagement of the homotrimeric TNF-R1 receptor by TNF enables recruitment of TRADD (TNF-R1 associated death
domain protein) via homotypic death domain interactions. TRADD associates with itself, TRAF2 and RIP1 (receptor-interacting protein 1) and with TRAF5. TNF-R2 is able to
directly associate with TRAF2, independently of TRADD. TRAF2 auto-poly-ubiquitinates and ubiquitinates RIP1. Poly-ubiquitination of RIP1 then leads to the recruitment of
TAK1, through interactions with TAB1, TAB2 and TAB3, again leading to NF-kB, p38 MAPK and JNK activation (Bradley, 2008; Verstrepen et al., 2008).
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activation of the NFkB transcription factor and JNK (c-Jun N-
terminal kinase) and p38 MAPK (mitogen-activated protein
kinase) signalling (Arend et al., 2008; Dinarello, 2009). Studies
with knockout mice have shown that at least one of the p50 or
p52 NFkB subunits is required for IL-1-induced osteoclast
formation and resorptive activity, indicating that much of the
osteoclastogenic activity of IL-1 is dependent on NFkB (Xing et al.,
2003). TNFa binds to two receptors, TNF type I (TNF-R1) and type
II (TNF-R2) receptor which differ in their signalling mechanisms
although there is substantial signalling crosstalk between the two
receptors (Aggarwal, 2003; Wajant et al., 2003). Interestingly, the
S. aureus virulence factor protein A, in addition to possession of
immunoglobulin G-binding activity, is able to bind to the TNF-R1
receptor and stimulates downstream signalling and inﬂammation
(Gomez et al., 2004). TNFa mediates the osteoclastogenic activity
of RANKL. TNFa production by osteoclast progenitors is induced
by RANKL and stimulates osteoclast differentiation in an autocrine
manner (Zou et al., 2001). Fig. 2 shows an overview of the signal
transduction events following IL-6 binding to its receptor. Signal
transduction involves the activation of Janus family (JAK) tyrosine
kinases and subsequent phosphorylation and activation of STAT
(signal transducers and activators of transcription) family
transcription factors (Kwan et al., 2004). IL-6 mediates bone
resorption indirectly, and has no effect on isolated osteoclasts and
IL-6 induction of osteoclastogenesis is dependent on the
expression of the IL-6 receptor by osteoblasts, but not osteoclast
progenitors (Hattersley et al., 1988; Kwan et al., 2004; Udagawa
et al., 1995).
It is clear that these cytokines have a prominent role in
modulating bone turnover, and perturbation of their levels can
have profound effects on this process. Although some mechanistic
details are currently lacking, there is strong evidence that S. aureus
infection of bone initiates local and systemic production of TNFa,
IL-1 and IL-6 via host PRRs. Elevated levels of these cytokines thenshift the homeostatic balance of bone turnover, increasing
osteoclast differentiation and bone resorption and diminishing
osteoblast-mediated bone matrix production and mineralisation,
thereby driving bone destruction.Staphylococcal invasion of bone cells
In addition to staphylococcal induction of inﬂammatory
mediators that modulate the actions of osteoblasts and osteo-
clasts, bacteria of this genus are involved in more direct
interactions with bone cells. Invasion and persistence of S. aureus
in ‘non-professional phagocytic’ host cells in vitro has been
described for many different cell types, including epithelial cells,
endothelial cells and keratinocytes (Garzoni and Kelley, 2009;
Kintarak et al., 2004). In cell culture systems, S. aureus is able to
invade cultured osteoblasts from murine, human and embryonic
chick sources, and S. epidermidis is also able to invade and grow
within cultured osteoblasts (Ellington et al., 1999; Hudson et al.,
1995; Jevon et al., 1999; Khalil et al., 2007; Reilly et al., 2000).
Electron microscopy has demonstrated the presence of bacteria
within osteoblasts and osteocytes of embryonic chicks following
injection with S. aureus, indicating that internalisation by bone
cells also occurs in vivo (Reilly et al., 2000). Intracellular bacteria
inside osteoblasts and osteocytes in a patient with recurrent,
long-term osteomyelitis of the ﬁbula have been visualised by light
and electron microscopy, although the species was unfortunately
not determined (Bosse et al., 2005). More recently Stoodley et al.
(2008), have demonstrated S. aureus bioﬁlms in an infected total
joint arthroplasty. Although not reported in this paper the authors
also identiﬁed S. aureus within host cells (personal communica-
tions, Stoodley). Thus the suggestion that internalisation of
S. aureus by bone cells in vivo provides a protective niche for
the bacterium, where it is shielded from immune effector
mechanisms and antibiotics, may help to explain persistent cases
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Fig. 2. Schematic diagram of IL-6 signalling events. IL-6 speciﬁcally binds to IL-6 receptor a (IL-6Ra), and recruits a homodimer of the gp130 signal-transducing protein
(Naugler and Karin, 2008). This in turn leads to association of the JAK kinases JAK1, JAK2 and TYK2 with gp130, and the autophosphorylation of these kinases (Heinrich et
al., 2003). JAK1 is of particular importance in IL-6 signalling, and cells deﬁcient in this kinase exhibit substantial signalling impairment (Guschin et al., 1995; Heinrich et al.,
2001; Rodig et al., 1998). Following JAK activation, gp130 is phosphorylated on multiple tyrosine residues, enabling recruitment and phosphorylation of STAT family
transcripton factors. STAT3 is the major transcription factor acting downstream of IL-6 signalling, and dimerises upon phosphorylation and translocates to the nucleus to
activate transcription of an array of target genes (Li et al., 2002; Naugler and Karin, 2008). IL-6 also activates the MAPK pathway, via JAK phosphorylation of SHP2 (SH2
domain-containing protein-tyrosine phosphatase). SHP2 is thought to recruit either the Grb2-SOS (growth factor receptor-bound protein/Son of Sevenless) complex and/or
Gab1 (Grb2-associated binder 1) to gp130. Recruitment of SOS then enables activation of Ras and subsequently the MAPK (mitogen-associated protein kinase) pathway,
although the importance of this pathway is currently unclear (Heinrich et al., 2003; Naugler and Karin, 2008).
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staphylococci in clinical osteomyelitis has yet to be established
(Henderson and Nair, 2003).
S. aureus requires ﬁbronectin-binding proteins (FnBPs) expressed
on the surface of the bacterium to enable uptake by osteoblasts, and
many other cell types (Ahmed et al., 2001; Garzoni and Kelley, 2009;
Sinha et al., 1999). These proteins belong to a group of adhesins
known as MSCRAMMs (microbial surface components recognising
adhesive matrix molecules), which bind a range of extracellular
matrix proteins including ﬁbronectin, ﬁbrinogen, collagen, elastin
and bone sialoprotein (Hauck and Ohlsen, 2006). Mutants deﬁcient
in the two FnBPs, FnBPA and FnBPB invade host cells very poorly
(Ahmed et al., 2001; Sinha et al., 1999). Invasion is dependent on
ﬁbronectin binding by these proteins, and on the host cell integrin
a5b1 receptor (Dziewanowska et al., 1999; Fowler et al., 2000; Sinha
et al., 1999). S. aureus binds to ﬁbronectin via FnBPs displayed on the
bacterial surface, and ﬁbronectin serves as a bridging molecule to
the integrin a5b1 which acts as a ‘‘phagocytic’’ receptor (Sinha et al.,
1999). Alternative uptake mechanisms do exist in certain cell types,
however, as S. aureus is still able to invade primary keratinocytes in
the absence of FnBPs and uptake is not inhibited by blockade of
integrin a5b1 binding to ﬁbronectin (Kintarak et al., 2004). The
mechanism of invasion also differs between S. aureus and
S. epidermidis and the latter does not gain entry via the ﬁbronec-
tin-integrin a5b1 mechanism (Khalil et al., 2007). The level of
expression of the alternative sigma factor,sB, affects fnbA expression
and the ﬁbronectin binding ability of S. aureus strains and correlates
with the level of internalisation of bacteria by osteoblasts suggesting
that sB-mediated up-regulation of FnBP expression may facilitate
invasion (Mitchell et al., 2008; Nair et al., 2003).
Integrin a5b1-mediated uptake of S. aureus requires remodel-
ling of the actin cytoskeleton (Agerer et al., 2005). The integrin-
linked kinase, ILK, provides a link between a5b1 and thecytoskeleton, and interacts with the cytoplasmic domains of b
integrins and is subsequently activated. ILK activity is required for
internalisation of S. aureus by epithelial cells (Wang et al., 2006).
Recruitment of focal adhesion proteins, including the adaptor
protein paxillin and the focal adhesion kinase, FAK, follows
(Boulter and Van Obberghen-Schilling, 2006). Upon infection of
HEK293T cells with S. aureus there is also recruitment of focal
adhesion proteins, such as tensin, zyxin and vinculin to the site of
bacterial attachment. FAK is recruited and tyrosine phosphory-
lated, and FAK-deﬁcient cells are able to internalise S. aureusmuch
less efﬁciently. Phosphorylation of downstream substrates of FAK,
including cortactin, which is involved in actin cytoskeletal
organisation, occurs during invasion, and interference with
cortactin also reduces internalisation. So, signalling downstream
of the integrin a5b1 receptor, involving ILK and FAK, is important
for S. aureus invasion, at least in certain cell types (Agerer et al.,
2005; Wang et al., 2006). Fig. 3 shows an overview of some of the
events involved in the internalisation of S. aureus by host cells.
Physical contact between S. aureus and osteoblasts induces
host cell expression of tumour necrosis factor apoptosis inducing
ligand (TRAIL) (Alexander et al., 2003). TRAIL is a member of the
TNF cytokine family, and binds to two death domain-containing
receptors, TRAIL receptors 1 and 2, which once activated recruit
the FADD (Fas-associated protein with death domain) adaptor
protein which in turn activates caspases 8 and 10 and commits
the cell to an apoptotic pathway (Mahalingam et al., 2009). TRAIL
produced by S. aureus-infected osteoblasts induces caspase-8
activation and apoptosis in cultured osteoblasts (Alexander et al.,
2003). Uninfected osteoblasts cultured alongside infected cells
also express TRAIL (Reott Jr., et al., 2008). TRAIL can induce
apoptosis in human osteoclasts via TRAIL receptor 2, and also
inhibits osteoclast differentiation (Colucci et al., 2007; Zauli et al.,
2004). It is therefore possible that apoptosis of bone cells infected
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Fig. 3. Schematic diagram of some of the signalling events involved in invasion of ‘non-professional phagocytic’ host cells by S. aureus. FnBPs expressed on the bacterial
surface bind to ﬁbronectin molecules in the extracellular matrix, which form a bridge with integrin a5b1 on the host cell membrane (Dziewanowska et al., 1999; Fowler et
al., 2000; Sinha et al., 1999). Ligation of this complex to the integrin receptor causes receptor clustering and subsequent activation of ILK, via interaction with the b1 subunit
(Wang et al., 2006). There is subsequent recruitment of paxillin and FAK and downstream phosphorylation of cortactin leading to remodelling of the actin cytoskeleton to
enable bacterial uptake (Agerer et al., 2005). The focal adhesion proteins zyxin, vinculin and tensin are also recruited to the site of bacterial uptake, the latter two potentially
via interactions with paxillin and FAK, respectively (Agerer et al., 2005).
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may contribute to bone loss in osteomyelitis (Henderson and Nair,
2003).
Growing experimental support indicates that staphylococcal
invasion of osteoblasts, most likely via the FnBP-ﬁbronectin-
integrin a5b1 bridging mechanism in the case of S. aureus, may
play a role in the pathogenesis of bone infections. This
intracellular location may provide a protected environment for
bacteria, aiding prolonged persistence by enabling evasion of
antimicrobials and host immune mechanisms and possibly
contributing to bone damage by inducing apoptosis of infected
cells.Staphylococcal virulence determinants
A number of animal models of bone implant infection,
osteomyelitis and septic arthritis have been developed which
have enabled the role of speciﬁc virulence factors in infections to
be determined. As mentioned at the outset there are a number of
routes of bone infection, i.e. haematogenous, contiguous and
direct infection of bone, and models have been developed to
mimic each of these routes of infection. This is important since the
range of environments experienced by the bacterium differs for
each route and hence the virulence factors that are involved in
pathology may be different for each route of infection. The septic
arthritis model developed by Tarkowski and colleagues (Bremellet al., 1991, 1992; Tarkowski et al., 2001) in conjunction with
deﬁned isogenic mutants deﬁcient in one or more virulence
determinants, or with neutralising antibodies to virulence factors
has proven to be particularly useful in elucidating the role of
speciﬁc virulence determinants and host factors in bone infec-
tions. This model has shown that there is a plethora of virulence
determinants involved in S. aureus septic arthritis (Table 1) some
of which are also involved in osteomyelitis (Table 1). However,
there is some controversy in this area because whilst the murine
septic arthritis model is well established and standardised a
number of different models have been developed for osteomyelitis
and the relevance of speciﬁc virulence factors to bone implant
infections or osteomyelitis appears to be dependent on the
particular model used. For example the collagen adhesin Cna
has been shown to contribute to osteomyelitis by some workers
(Elasri et al., 2002) but not by others (Johansson et al., 2001) and
has been reported not to be important in orthopaedic device
infections (Darouiche et al., 1997). The role of FnBPs has not been
directly assessed in a model of osteomyelitis, but comparison of
S. aureus strains with and without ﬁbronectin-binding activity in a
mouse osteomyelitis model suggests that ﬁbronectin-binding
strains may give rise to more severe bone infections (Johansson
et al., 2001). In the septic arthritis model, S. aureus fnbA fnbB
mutants show no reduction in severity of arthritis, in contrast
with clfA clfB mutants lacking the ﬁbrinogen-binding clumping
factors. However, the presence of the fnb genes results in greater
weight loss and mortality, as well as higher serum levels of IL-6,
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Table 1
Virulence determinants which have been demonstrated to play a role in the pathology of experimental S. aureus bone infections. Most studies have utilised the murine
model of septic arthritis.
Virulence determinant Model Reference
Accessory gene regulator (agr) A, O Abdelnour et al., 1993; Blevins et al., 2003; Gillaspy et al., 1995
Alpha-toxin and gamma-toxin A Gemmell et al., 1997; Nilsson et al., 1999
Collagen adhesin (Cna) A, O Elasri et al., 2002; Nilsson et al., 1998; Patti et al., 1994; Xu et al., 2004
Clumping factor (ClfA) A Josefsson et al., 2001; Palmqvist et al., 2004, 2005
Capsular polysaccharide A Nilsson et al., 1997
DltA (D-alanine modiﬁcation of teichoic acid) A Collins et al., 2002
Fibronectin-binding proteins O Johansson et al., 2001
MgrA (a global regulator) A Jonsson et al., 2008
MprF (L-lysine modiﬁcation of membrane lipids) A Peschel et al., 2001
Peptidoglycan A Liu et al., 2001
Pls (plasmin-sensitive protein) A Josefsson et al., 2005
Protein A A Gemmell et al., 1997; Palmqvist et al., 2002
Ribonucleotide reductase class III A Kirdis et al., 2007
Sigma factor B (sB) and sigma factor S (ss) Jonsson et al., 2004; Shaw et al., 2008
Sortase SrtA (responsible for anchoring many adhesins to the bacterial cell wall) A Jonsson et al., 2002
Small colony variant phenotype A Jonsson et al., 2003
Staphylococcal accessory regulator A, O Blevins et al., 2003
Staphylococcal DNA A Deng et al., 1999
Staphylococcal superantigens A Abdelnour et al., 1994; Bremell and Tarkowski, 1995
Two putative lytic transglycosylases, IsaA and SceD A Stapleton et al., 2007
A, arthritis; O, osteomyelitis.
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(Palmqvist et al., 2005).
One area of research that has received surprisingly little
attention is that of the direct action of virulence factors on bone
and bone cells. Work in our own laboratory has shown that
S. aureus and S. epidermidis produce surface-associated proteins
that can stimulate bone breakdown in an in vitro assay (Meghji
et al., 1997; Nair et al., 1995). These surface-associated proteins
and capsular material appear to promote the formation and
activation of the bone-resorbing osteoclast (Lau et al., 2006;
Meghji et al., 1998). Interestingly, a proportion of the population
have antibodies that can block the action of the S. aureus proteins
and prevent bone breakdown (Nair et al., 1997). The identity of the
protein(s) in these mixtures which cause bone destruction has not
been elucidated.Small colony variants
Variant forms of S. aureus, known as small colony variants
(SCVs), are associated with infections of bone and joint that may
be particularly persistent, recurrent and refractory to antibiotic
treatment (von Eiff et al., 2006). These bacteria are mutant forms
of Staphylococcus that may have an adaptive advantage enabling
persistent bone colonisation. SCV forms of coagulase-negative
staphylococci, including S. epidermidis, S. lugdunensis and S. capitis
have also been isolated from a range of infections (Adler et al.,
2003; Seifert et al., 2005; von Eiff et al., 1999, 2006). The SCV
phenotype is characterised by slow growth, with colonies around
10-fold smaller than wild-type forms, often with decreased
pigmentation, increased aminoglycoside resistance and some
reports of reduced haemolytic activity (Sendi and Proctor, 2009).
The nature of these phenotypes can cause difﬁculty in detection
and identiﬁcation of the bacteria, and may contribute to an
underestimation of the clinical prevalence of SCVs (von Eiff,
2008). These phenotypes usually result from auxotrophy for
hemin, menadione or thymidine and can be reversed by
supplementation with these molecules (Proctor et al., 1995,
2006). Mutations in the hemB and menD genes produce hemin
and menadione auxotrophic strains with typical SCV phenotypes,and give rise to disruption of electron transport which is the basis
of the growth deﬁciency, increased aminoglycoside resistance and
other phenotypes (Bates et al., 2003; Proctor et al., 2006; von Eiff
et al., 1997b). SCVs can be selected for with gentamicin in vitro,
and there is evidence that antibiotic therapy, in particular use of
gentamicin beads, which are used in addition to debridement and
systemic antibiotic therapy for osteomyelitis may select for SCVs
in clinical situations (Musher et al., 1977; von Eiff et al., 1997a). In
a cohort of fourteen patients with conﬁrmed S. aureus osteomye-
litis, SCVs were isolated only from those four that had received
gentamicin bead therapy, with the remaining ten patients
harbouring normal S. aureus strains. Of the four SCVs, three were
auxotrophic for hemin, and one for menadione. Only the patients
harbouring SCVs had recurrent infections, although only patients
whose gentamicin bead therapy had failed were included in the
study (von Eiff et al., 1997a). SCVs have also been isolated from
cases of infection of hip prostheses, and intracellular bacteria
within host ﬁbroblasts were identiﬁed in one of the ﬁve instances
(Sendi et al., 2006).
Clinically isolated SCVs with hemin auxotrophy, and deﬁned
hemBmutants, show enhanced intracellular persistence in a range
of human cell types (Moisan et al., 2006; Vaudaux et al., 2002; von
Eiff et al., 1997b, 2001). The basis of this persistence is not
established but may involve a number of possible mechanisms.
S. aureus hemB mutants exhibit enhanced binding to ﬁbrinogen
and ﬁbronectin, and transcribe and display more ClfA and FnBP on
their surface, which may increase attachment and uptake by host
cells (Vaudaux et al., 2002). Transcriptional proﬁling of clinical
and deﬁned mutant SCVs reveals increased transcription of genes
regulated by sB, including adhesin genes, and down-regulation of
exoprotein and toxin genes (Moisan et al., 2006). The effect of
increased sB activity on MSCRAMM expression has been shown to
correlate well with osteoblast invasion, adding weight to the
argument that sB-mediated up-regulation of adhesins increases
host cell invasion, at least in vitro, and that increased invasion by
SCVs may be partially dependent on this mechanism (Moisan
et al., 2006; Nair et al., 2003). It has been argued that reduced
production of toxins, particularly haemolysins, by SCVs also
contributes to intracellular persistence by reducing the cytotoxic
effect on host cells (Moisan et al., 2006; Sendi and Proctor, 2009;
von Eiff et al., 1997b).
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mutant, exhibiting the SCV phenotype, elicited more frequent and
severe arthritis than the parental strain despite a reduced
bacterial load in the kidney and joints. It has been argued that
SCVs are therefore more virulent on a ‘per organism’ basis and
that enhanced protease production by hemB mutants may
partially explain this (Jonsson et al., 2003). It may be that in
clinical infections relatively small numbers of SCVs with enhanced
virulence survive within tissues, possibly intracellularly, for
extended periods and cause persistent infections. Clinically
isolated SCVs are able to revert to the parent phenotype, although
to what extent this may play a role in infections, and whether
S. aureus may ‘switch’ between states in different in vivo
situations is currently unclear.Conclusions
Staphylococcus species are a major cause of debilitating bone
disease globally, a situation that shows no sign of abating. The
increasing antibiotic resistance of staphylococci, combined with
the greater opportunity for infection afforded by escalating
numbers of orthopaedic surgical procedures will only serve to
exacerbate the problem. Furthermore, evidence is now emerging
that staphylococci are facultative intracellular pathogens, and are
able to exploit this protected niche during bone infection to
enhance persistence. Spontaneously arising mutant forms, such as
SCVs, may be particularly adapted to this lifestyle, complicating
the treatment of these infections further. Although host factors
involved in the inﬂammatory destruction of bone are increasingly
well understood, the staphylococcal virulence determinants
directly involved in skeletal colonisation and destruction are less
well characterised. Continued focus on elucidating the complex
interactions between host and pathogen in these invasive skeletal
infections is required to develop more effective treatment
regimes. Enhanced understanding of these interactions will not
only inform improved clinical management of bone disease, but
may well open up new avenues for therapeutic development.Acknowledgement
We are grateful to the Arthritis Research Campaign for project
grant funding (grant number 18294).
References
Abdelnour, A., Arvidson, S., Bremell, T., Ryden, C., Tarkowski, A., 1993. The
accessory gene regulator (agr) controls Staphylococcus aureus virulence in a
murine arthritis model. Infect. Immun. 61, 3879–3885.
Abdelnour, A., Bremell, T., Tarkowski, A., 1994. Toxic shock syndrome toxin 1
contributes to the arthritogenicity of Staphylococcus aureus. J. Infect. Dis. 170,
94–99.
Adler, H., Widmer, A., Frei, R., 2003. Emergence of a teicoplanin-resistant small
colony variant of Staphylococcus epidermidis during vancomycin therapy. Eur. J.
Clin. Microbiol. Infect. Dis. 22, 746–748.
Agerer, F., Lux, S., Michel, A., Rohde, M., Ohlsen, K., Hauck, C.R., 2005. Cellular
invasion by Staphylococcus aureus reveals a functional link between focal
adhesion kinase and cortactin in integrin-mediated internalisation. J. Cell Sci.
118, 2189–2200.
Aggarwal, B.B., 2003. Signalling pathways of the TNF superfamily: a double-edged
sword. Nat. Rev. Immunol. 3, 745–756.
Ahmed, S., Meghji, S., Williams, R.J., Henderson, B., Brock, J.H., Nair, S.P., 2001.
Staphylococcus aureus ﬁbronectin binding proteins are essential for internali-
zation by osteoblasts but do not account for differences in intracellular levels
of bacteria. Infect. Immun. 69, 2872–2877.
Al Arfaj, A.S., 2008. A prospective study of the incidence and characteristics of
septic arthritis in a teaching hospital in Riyadh, Saudi Arabia. Clin. Rheumatol.
27, 1403–1410.
Alexander, E.H., Rivera, F.A., Marriott, I., Anguita, J., Bost, K.L., Hudson, M.C., 2003.
Staphylococcus aureus-induced tumor necrosis factor-related apoptosis-indu-cing ligand expression mediates apoptosis and caspase-8 activation in infected
osteoblasts. BMC Microbiol. 3, 5.
Angel, N.Z., Walsh, N., Forwood, M.R., Ostrowski, M.C., Cassady, A.I., Hume, D.A.,
2000. Transgenic mice overexpressing tartrate-resistant acid phosphatase
exhibit an increased rate of bone turnover. J. Bone Miner. Res. 15, 103–110.
Arciola, C.R., Campoccia, D., Gamberini, S., Baldassarri, L., Montanaro, L., 2005.
Prevalence of cna, fnbA and fnbB adhesin genes among Staphylococcus aureus
isolates from orthopedic infections associated to different types of implant.
FEMS Microbiol. Lett. 246, 81–86.
Arend, W.P., Palmer, G., Gabay, C., 2008. IL-1, IL-18, and IL-33 families of cytokines.
Immunol. Rev. 223, 20–38.
Arnold, S.R., Elias, D., Buckingham, S.C., Thomas, E.D., Novias, E., Arkader, A.,
Howard, C., 2006. Changing patterns of acute hematogenous osteomyelitis and
septic arthritis: emergence of community-associated methicillin-resistant
Staphylococcus aureus. J. Pediatr. Orthop. 26, 703–708.
Assuma, R., Oates, T., Cochran, D., Amar, S., Graves, D.T., 1998. IL-1 and TNF
antagonists inhibit the inﬂammatory response and bone loss in experimental
periodontitis. J. Immunol. 160, 403–409.
Azuma, Y., Kaji, K., Katogi, R., Takeshita, S., Kudo, A., 2000. Tumor necrosis factor-
alpha induces differentiation of and bone resorption by osteoclasts. J. Biol.
Chem. 275, 4858–4864.
Bates, D.M., von, E.C., McNamara, P.J., Peters, G., Yeaman, M.R., Bayer, A.S., Proctor,
R.A., 2003. Staphylococcus aureus menD and hemB mutants are as infective as
the parent strains, but the menadione biosynthetic mutant persists within the
kidney. J. Infect. Dis. 187, 1654–1661.
Bennet, G.C., Bennet, S.J., 2006. Infection of bone and joint. Surgery (Oxford) 24,
211–214.
Berendt, T., Byren, I., 2004. Bone and joint infection. Clin. Med. 4, 510–518.
Blair, H.C., 1998. How the osteoclast degrades bone. Bioessays 20, 837–846.
Blair, H.C., Teitelbaum, S.L., Ghiselli, R., Gluck, S., 1989. Osteoclastic bone resorption
by a polarized vacuolar proton pump. Science 245, 855–857.
Blevins, J.S., Elasri, M.O., Allmendinger, S.D., Beenken, K.E., Skinner, R.A., Thomas,
J.R., Smeltzer, M.S., 2003. Role of sarA in the pathogenesis of Staphylococcus
aureus musculoskeletal infection. Infect. Immun. 71, 516–523.
Blyth, M.J., Kincaid, R., Craigen, M.A., Bennet, G.C., 2001. The changing
epidemiology of acute and subacute haematogenous osteomyelitis in children.
J. Bone Joint Surg. Br. 83, 99–102.
Bocchini, C.E., Hulten, K.G., Mason Jr., E.O., Gonzalez, B.E., Hammerman, W.A.,
Kaplan, S.L., 2006. Panton-Valentine leukocidin genes are associated with
enhanced inﬂammatory response and local disease in acute hematogenous
Staphylococcus aureus osteomyelitis in children. Pediatrics 117, 433–440.
Bossard, M.J., Tomaszek, T.A., Thompson, S.K., Amegadzie, B.Y., Hanning, C.R., Jones,
C., Kurdyla, J.T., McNulty, D.E., Drake, F.H., Gowen, M., Levy, M.A., 1996.
Proteolytic activity of human osteoclast cathepsin K. Expression, puriﬁcation,
activation, and substrate identiﬁcation. J. Biol. Chem. 271, 12517–12524.
Bosse, M.J., Gruber, H.E., Ramp, W.K., 2005. Internalization of bacteria by
osteoblasts in a patient with recurrent, long-term osteomyelitis. A case report.
J. Bone Joint Surg. Am. 87, 1343–1347.
Bost, K.L., Ramp, W.K., Nicholson, N.C., Bento, J.L., Marriott, I., Hudson, M.C., 1999.
Staphylococcus aureus infection of mouse or human osteoblasts induces high levels
of interleukin-6 and interleukin-12 production. J. Infect. Dis. 180, 1912–1920.
Boulter, E., Van Obberghen-Schilling, E., 2006. Integrin-linked kinase and its
partners: a modular platform regulating cell-matrix adhesion dynamics and
cytoskeletal organization. Eur. J. Cell Biol. 85, 255–263.
Boyce, B.F., Xing, L., 2008. Functions of RANKL/RANK/OPG in bone modeling and
remodeling. Arch. Biochem. Biophys. 473, 139–146.
Boyden, E.D., Dietrich, W.F., 2006. Nalp1b controls mouse macrophage suscep-
tibility to anthrax lethal toxin. Nat. Genet. 38, 240–244.
Bradley, J.R., 2008. TNF-mediated inﬂammatory disease. J. Pathol. 214, 149–160.
Bremell, T., Tarkowski, A., 1995. Preferential induction of septic arthritis and mortality
by superantigen-producing staphylococci. Infect. Immun. 63, 4185–4187.
Bremell, T., Lange, S., Yacoub, A., Ryden, C., Tarkowski, A., 1991. Experimental
Staphylococcus aureus arthritis in mice. Infect. Immun. 59, 2615–2623.
Bremell, T., Abdelnour, A., Tarkowski, A., 1992. Histopathological and serological
progression of experimental Staphylococcus aureus arthritis. Infect. Immun. 60,
2976–2985.
Bu, R., Borysenko, C.W., Li, Y., Cao, L., Sabokbar, A., Blair, H.C., 2003. Expression and
function of TNF-family proteins and receptors in human osteoblasts. Bone 33,
760–770.
Canalis, E., 1987. Effects of tumor necrosis factor on bone formation in vitro.
Endocrinology 121, 1596–1604.
Cassat, J.E., Dunman, P.M., McAleese, F., Murphy, E., Projan, S.J., Smeltzer, M.S.,
2005. Comparative genomics of Staphylococcus aureus musculoskeletal iso-
lates. J. Bacteriol. 187, 576–592.
Centrella, M., McCarthy, T.L., Canalis, E., 1988. Tumor necrosis factor-alpha inhibits
collagen synthesis and alkaline phosphatase activity independently of its effect
on deoxyribonucleic acid synthesis in osteoblast-enriched bone cell cultures.
Endocrinology 123, 1442–1448.
Chiang, C.Y., Kyritsis, G., Graves, D.T., Amar, S., 1999. Interleukin-1 and tumor
necrosis factor activities partially account for calvarial bone resorption induced
by local injection of lipopolysaccharide. Infect. Immun. 67, 4231–4236.
Ciampolini, J., Harding, K.G., 2000. Pathophysiology of chronic bacterial osteo-
myelitis. Why do antibiotics fail so often?. Postgrad. Med. J. 76, 479–483.
Collins, L.V., Kristian, S.A., Weidenmaier, C., Faigle, M., van Kessel, K.P., van Strijp,
J.A., Gotz, F., Neumeister, B., Peschel, A., 2002. Staphylococcus aureus strains
lacking D-alanine modiﬁcations of teichoic acids are highly susceptible to
ARTICLE IN PRESS
J.A. Wright, S.P. Nair / International Journal of Medical Microbiology 300 (2010) 193–204202human neutrophil killing and are virulence attenuated in mice. J. Infect. Dis.
186, 214–219.
Colucci, S., Brunetti, G., Cantatore, F.P., Oranger, A., Mori, G., Pignataro, P., Tamma,
R., Grassi, F.R., Zallone, A., Grano, M., 2007. The death receptor DR5 is involved
in TRAIL-mediated human osteoclast apoptosis. Apoptosis 12, 1623–1632.
Creagh, E.M., O’Neill, L.A., 2006. TLRs, NLRs and RLRs: a trinity of pathogen sensors
that co-operate in innate immunity. Trends Immunol. 27, 352–357.
Darouiche, R.O., Landon, G.C., Patti, J.M., Nguyen, L.L., Fernau, R.C., McDevitt, D.,
Greene, C., Foster, T., Klima, M., 1997. Role of Staphylococcus aureus surface
adhesins in orthopaedic device infections: are results model-dependent?
J. Med. Microbiol. 46, 75–79.
Deng, G.M., Nilsson, I.M., Verdrengh, M., Collins, L.V., Tarkowski, A., 1999. Intra-
articularly localized bacterial DNA containing CpG motifs induces arthritis.
Nat. Med. 5, 702–705.
Dinarello, C.A., 2009. Immunological and inﬂammatory functions of the inter-
leukin-1 family. Annu. Rev. Immunol. 27, 519–550.
Drake, F.H., Dodds, R.A., James, I.E., Connor, J.R., Debouck, C., Richardson, S.,
Lee-Rykaczewski, E., Coleman, L., Rieman, D., Barthlow, R., Hastings, G., Gowen,
M., 1996. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in
human osteoclasts. J. Biol. Chem. 271, 12511–12516.
Dubost, J.J., Soubrier, M., De, C.C., Ristori, J.M., Bussiere, J.L., Sauvezie, B., 2002. No
changes in the distribution of organisms responsible for septic arthritis over a
20 year period. Ann. Rheum. Dis. 61, 267–269.
Dziewanowska, K., Patti, J.M., Deobald, C.F., Bayles, K.W., Trumble, W.R., Bohach,
G.A., 1999. Fibronectin binding protein and host cell tyrosine kinase are
required for internalization of Staphylococcus aureus by epithelial cells. Infect.
Immun. 67, 4673–4678.
Ek-Rylander, B., Bill, P., Norgard, M., Nilsson, S., Andersson, G., 1991. Cloning,
sequence, and developmental expression of a type 5, tartrate-resistant, acid
phosphatase of rat bone. J. Biol. Chem. 266, 24684–24689.
Elasri, M.O., Thomas, J.R., Skinner, R.A., Blevins, J.S., Beenken, K.E., Nelson, C.L.,
Smeltzer, M.S., 2002. Staphylococcus aureus collagen adhesin contributes to the
pathogenesis of osteomyelitis. Bone 30, 275–280.
Ellington, J.K., Reilly, S.S., Ramp, W.K., Smeltzer, M.S., Kellam, J.F., Hudson, M.C.,
1999. Mechanisms of Staphylococcus aureus invasion of cultured osteoblasts.
Microb. Pathog. 26, 317–323.
Evans, C.A., Jellis, J., Hughes, S.P., Remick, D.G., Friedland, J.S., 1998. Tumor necrosis
factor-alpha, interleukin-6, and interleukin-8 secretion and the acute-phase
response in patients with bacterial and tuberculous osteomyelitis. J. Infect. Dis.
177, 1582–1587.
Everts, V., Korper, W., Hoeben, K.A., Jansen, I.D., Bromme, D., Cleutjens, K.B.,
Heeneman, S., Peters, C., Reinheckel, T., Saftig, P., Beertsen, W., 2006.
Osteoclastic bone degradation and the role of different cysteine proteinases
and matrix metalloproteinases: differences between calvaria and long bone. J.
Bone Miner. Res. 21, 1399–1408.
Faustin, B., Lartigue, L., Bruey, J.M., Luciano, F., Sergienko, E., Bailly-Maitre, B.,
Volkmann, N., Hanein, D., Rouiller, I., Reed, J.C., 2007. Reconstituted NALP1
inﬂammasome reveals two-step mechanism of caspase-1 activation. Mol. Cell
25, 713–724.
Feil, E.J., Cooper, J.E., Grundmann, H., Robinson, D.A., Enright, M.C., Berendt, T.,
Peacock, S.J., Smith, J.M., Murphy, M., Spratt, B.G., Moore, C.E., Day, N.P., 2003.
How clonal is Staphylococcus aureus?. J. Bacteriol. 185, 3307–3316.
Fowler, T., Wann, E.R., Joh, D., Johansson, S., Foster, T.J., Hook, M., 2000. Cellular
invasion by Staphylococcus aureus involves a ﬁbronectin bridge between the
bacterial ﬁbronectin-binding MSCRAMMs and host cell beta1 integrins. Eur. J.
Cell Biol. 79, 672–679.
Franchi, L., Amer, A., Body-Malapel, M., Kanneganti, T.D., Ozoren, N., Jagirdar, R.,
Inohara, N., Vandenabeele, P., Bertin, J., Coyle, A., Grant, E.P., Nunez, G., 2006.
Cytosolic ﬂagellin requires Ipaf for activation of caspase-1 and interleukin
1[beta] in Salmonella-infected macrophages. Nat. Immunol. 7, 576–582.
Gallie, W., 1951. First recurrence of osteomyelitis eighty years after infection. J.
Bone Joint Surg. Br. 33-B, 110–111.
Garcia-Alvarez, F., Navarro-Zorraquino, M., Castro, A., Grasa, J.M., Pastor, C.,
Monzon, M., Martinez, A., Garcia-Alvarez, I., Castillo, J., Lozano, R., 2009. Effect
of age on cytokine response in an experimental model of osteomyelitis.
Biogerontology 10, 649–658.
Garzoni, C., Kelley, W.L., 2009. Staphylococcus aureus: new evidence for
intracellular persistence. Trends Microbiol. 17, 59–65.
Gemmell, C.G., Goutcher, S.C., Reid, R., Sturrock, R.D., 1997. Role of certain virulence
factors in a murine model of Staphylococcus aureus arthritis. J. Med. Microbiol.
46, 208–213.
Gillaspy, A.F., Hickmon, S.G., Skinner, R.A., Thomas, J.R., Nelson, C.L., Smeltzer, M.S.,
1995. Role of the accessory gene regulator (agr) in pathogenesis of
staphylococcal osteomyelitis. Infect. Immun. 63, 3373–3380.
Gillespie, W.J., 1990. Epidemiology in bone and joint infection. Infect. Dis. Clin.
North Am. 4, 361–376.
Goldenberg, D.L., 1998. Septic arthritis. Lancet 351, 197–202.
Gomez, M.I., Lee, A., Reddy, B., Muir, A., Soong, G., Pitt, A., Cheung, A., Prince, A.,
2004. Staphylococcus aureus protein A induces airway epithelial inﬂammatory
responses by activating TNFR1. Nat. Med. 10, 842–848.
Grammatico, L., Baron, S., Rusch, E., Lepage, B., Surer, N., Desenclos, J.C., Besnier,
J.M., 2008. Epidemiology of vertebral osteomyelitis (VO) in France: analysis of
hospital-discharge data 2002–2008. Epidemiol. Infect. 136, 653–660.
Greer, R.B., Rosenberg, A.E., 1993. Case 6 – 1993 – A 69-year-old woman with a
sclerotic lesion of the femur and pulmonary nodules. N. Engl. J. Med. 328,
422–428.Greig, J.M., Wood, M.J., 2003. Staphylococcus lugdunensis vertebral osteomyelitis.
Clin. Microbiol. Infect. 9, 1139–1141.
Guschin, D., Rogers, N., Briscoe, J., Witthuhn, B., Watling, D., Horn, F., Pellegrini, S.,
Yasukawa, K., Heinrich, P., Stark, G.R., 1995. A major role for the protein
tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response
to interleukin-6. EMBO J. 14, 1421–1429.
Hattersley, G., Dorey, E., Horton, M.A., Chambers, T.J., 1988. Human macrophage
colony-stimulating factor inhibits bone resorption by osteoclasts disaggre-
gated from rat bone. J. Cell. Physiol. 137, 199–203.
Hauck, C.R., Ohlsen, K., 2006. Sticky connections: extracellular matrix protein
recognition and integrin-mediated cellular invasion by Staphylococcus aureus.
Curr. Opin. Microbiol. 9, 5–11.
Hayman, A.R., Cox, T.M., 1994. Purple acid phosphatase of the human macrophage
and osteoclast. Characterization, molecular properties, and crystallization of
the recombinant di-iron-oxo protein secreted by baculovirus-infected insect
cells. J. Biol. Chem. 269, 1294–1300.
Hayman, A.R., Jones, S.J., Boyde, A., Foster, D., Colledge, W.H., Carlton, M.B., Evans,
M.J., Cox, T.M., 1996. Mice lacking tartrate-resistant acid phosphatase (Acp 5)
have disrupted endochondral ossiﬁcation and mild osteopetrosis. Develop-
ment 122, 3151–3162.
Heinrich, P.C., Bode, J., Decker, M., Graeve, L., Martens, A., Muller-Newen, G., Pﬂanz,
S., Schaper, F., Schmitz, J., 2001. Termination and modulation of IL-6-type
cytokine signaling. Adv. Exp. Med. Biol. 495, 153–160.
Heinrich, P.C., Behrmann, I., Haan, S., Hermanns, H.M., Muller-Newen, G., Schaper,
F., 2003. Principles of interleukin (IL)-6-type cytokine signalling and its
regulation. Biochem. J. 374, 1–20.
Henderson, B., Nair, S.P., 2003. Hard labour: bacterial infection of the skeleton.
Trends Microbiol. 11, 570–577.
Henriksen, K., Neutzsky-Wulff, A.V., Bonewald, L.F., Karsdal, M.A., 2009. Local
communication on and within bone controls bone remodeling. Bone 44,
1026–1033.
Hikita, A., Yana, I., Wakeyama, H., Nakamura, M., Kadono, Y., Oshima, Y., Nakamura,
K., Seiki, M., Tanaka, S., 2006. Negative regulation of osteoclastogenesis by
ectodomain shedding of receptor activator of NF-kappaB ligand. J. Biol. Chem.
281, 36846–36855.
Hudson, M.C., Ramp, W.K., Nicholson, N.C., Williams, A.S., Nousiainen, M.T., 1995.
Internalization of Staphylococcus aureus by cultured osteoblasts. Microb.
Pathog. 19, 409–419.
Ishimi, Y., Miyaura, C., Jin, C.H., Akatsu, T., Abe, E., Nakamura, Y., Yamaguchi, A.,
Yoshiki, S., Matsuda, T., Hirano, T., 1990. IL-6 is produced by osteoblasts and
induces bone resorption. J. Immunol. 145, 3297–3303.
Jevon, M., Guo, C., Ma, B., Mordan, N., Nair, S.P., Harris, M., Henderson, B., Bentley,
G., Meghji, S., 1999. Mechanisms of internalization of Staphylococcus aureus by
cultured human osteoblasts. Infect. Immun. 67, 2677–2681.
Johansson, A., Flock, J.I., Svensson, O., 2001. Collagen and ﬁbronectin binding in
experimental staphylococcal osteomyelitis. Clin. Orthop. Relat. Res., 241–246.
Jonsson, I.M., Mazmanian, S.K., Schneewind, O., Verdrengh, M., Bremell, T.,
Tarkowski, A., 2002. On the role of Staphylococcus aureus sortase and sortase-
catalyzed surface protein anchoring in murine septic arthritis. J. Infect. Dis.
185, 1417–1424.
Jonsson, I.M., vonEiff, C., Proctor, R.A., Peters, G., Ryden, C., Tarkowski, A., 2003.
Virulence of a hemB mutant displaying the phenotype of a Staphylococcus
aureus small colony variant in a murine model of septic arthritis. Microb.
Pathog. 34, 73–79.
Jonsson, I.M., Arvidson, S., Foster, S., Tarkowski, A., 2004. Sigma factor B and RsbU
are required for virulence in Staphylococcus aureus-induced arthritis and sepsis.
Infect. Immun. 72, 6106–6111.
Jonsson, I.M., Lindholm, C., Luong, T.T., Lee, C.Y., Tarkowski, A., 2008. mgrA
regulates staphylococcal virulence important for induction and progression of
septic arthritis and sepsis. Microbes Infect. 10, 1229–1235.
Josefsson, E., Hartford, O., O’Brien, L., Patti, J.M., Foster, T., 2001. Protection against
experimental Staphylococcus aureus arthritis by vaccination with clumping
factor A, a novel virulence determinant. J. Infect. Dis. 184, 1572–1580.
Josefsson, E., Juuti, K., Bokarewa, M., Kuusela, P., 2005. The surface protein Pls of
methicillin-resistant Staphylococcus aureus is a virulence factor in septic
arthritis. Infect. Immun. 73, 2812–2817.
Kahlenberg, J.M., Lundberg, K.C., Kertesy, S.B., Qu, Y., Dubyak, G.R., 2005.
Potentiation of caspase-1 activation by the P27 receptor is dependent on
TLR signals and requires NF-kappaB-driven protein synthesis. J. Immunol. 175,
7611–7622.
Kanazawa, K., Azuma, Y., Nakano, H., Kudo, A., 2003. TRAF5 functions in both
RANKL- and TNF-induced osteoclastogenesis. J. Bone Miner. Res. 18, 443–450.
Kanazawa, K., Kudo, A., 2005. TRAF2 is essential for TNF-alpha-induced
osteoclastogenesis. J. Bone Miner. Res. 20, 840–847.
Karwowska, A., Davies, H.D., Jadavji, T., 1998. Epidemiology and outcome of
osteomyelitis in the era of sequential intravenous-oral therapy. Pediatr. Infect.
Dis. J. 17, 1021–1026.
Khalil, H., Williams, R.J., Stenbeck, G., Henderson, B., Meghji, S., Nair, S.P., 2007.
Invasion of bone cells by Staphylococcus epidermidis. Microbes Infect. 9,
460–465.
Kim, H.H., Lee, D.E., Shin, J.N., Lee, Y.S., Jeon, Y.M., Chung, C.H., Ni, J., Kwon, B.S.,
Lee, Z.H., 1999. Receptor activator of NF-kappaB recruits multiple TRAF family
adaptors and activates c-Jun N-terminal kinase. FEBS Lett. 443, 297–302.
Kintarak, S., Whawell, S.A., Speight, P.M., Packer, S., Nair, S.P., 2004. Internalization
of Staphylococcus aureus by human keratinocytes. Infect. Immun. 72,
5668–5675.
ARTICLE IN PRESS
J.A. Wright, S.P. Nair / International Journal of Medical Microbiology 300 (2010) 193–204 203Kirdis, E., Jonsson, I.M., Kubica, M., Potempa, J., Josefsson, E., Masalha, M., Foster,
S.J., Tarkowski, A., 2007. Ribonucleotide reductase class III, an essential enzyme
for the anaerobic growth of Staphylococcus aureus, is a virulence determinant in
septic arthritis. Microb. Pathog. 43, 179–188.
Klosterhalfen, B., Peters, K.M., Tons, C., Hauptmann, S., Klein, C.L., Kirkpatrick, C.J.,
1996. Local and systemic inﬂammatory mediator release in patients with acute
and chronic posttraumatic osteomyelitis. J. Trauma 40, 372–378.
Konig, A., Muhlbauer, R.C., Fleisch, H., 1988. Tumor necrosis factor alpha and
interleukin-1 stimulate bone resorption in vivo as measured by urinary
[3H]tetracycline excretion from prelabeled mice. J. Bone Miner. Res. 3, 621–627.
Kornak, U., Kasper, D., Bosl, M.R., Kaiser, E., Schweizer, M., Schulz, A., Friedrich, W.,
Delling, G., Jentsch, T.J., 2001. Loss of the ClC-7 chloride channel leads to
osteopetrosis in mice and man. Cell 104, 205–215.
Korovessis, P., Fortis, A.P., Spastris, P., Droutsas, P., 1991. Acute osteomyelitis of the
patella 50 years after a knee fusion for septic arthritis. A case report. Clin.
Orthop. Relat. Res., 205–207.
Kotake, S., Sato, K., Kim, K.J., Takahashi, N., Udagawa, N., Nakamura, I., Yamaguchi,
A., Kishimoto, T., Suda, T., Kashiwazaki, S., 1996. Interleukin-6 and soluble
interleukin-6 receptors in the synovial ﬂuids from rheumatoid arthritis
patients are responsible for osteoclast-like cell formation. J. Bone Miner. Res.
11, 88–95.
Kwan, T.S., Padrines, M., Theoleyre, S., Heymann, D., Fortun, Y., 2004. IL-6, RANKL,
TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine
Growth Factor Rev. 15, 49–60.
Lacey, D.C., Simmons, P.J., Graves, S.E., Hamilton, J.A., 2008. Proinﬂammatory
cytokines inhibit osteogenic differentiation from stem cells: implications for
bone repair during inﬂammation. Osteoarthritis Cartilage 17, 735–742.
Lang, S., Livesley, M.A., Lambert, P.A., Elliott, J., Elliott, T.S., 1999. The genomic
diversity of coagulase-negative staphylococci associated with nosocomial
infections. J. Hosp. Infect. 43, 187–193.
Lau, Y.S., Wang, W., Sabokbar, A., Simpson, H., Nair, S., Henderson, B., Berendt, A.,
Athanasou, N.A., 2006. Staphylococcus aureus capsular material promotes
osteoclast formation. Injury 37 (Suppl. 2), S41–S48.
Lazzarini, L., Mader, J.T., Calhoun, J.H., 2004. Osteomyelitis in long bones. J. Bone
Joint Surg. Am. 86-A, 2305–2318.
Lee, K., Goodman, S.B., 2008. Current state and future of joint replacements in the
hip and knee. Expert Rev. Med. Devices 5, 383–393.
Levine, M., Siegel, L.B., 2003. A swollen joint: why all the fuss?. Am. J. Ther. 10,
219–224.
Lew, D.P., Waldvogel, F.A., 1997. Osteomyelitis. N. Engl. J. Med. 336, 999–1007.
Lew, D.P., Waldvogel, F.A., 2004. Osteomyelitis. Lancet 364, 369–379.
Li, W., Liang, X., Kellendonk, C., Poli, V., Taub, R., 2002. STAT3 contributes to the
mitogenic response of hepatocytes during liver regeneration. J. Biol. Chem. 277,
28411–28417.
Li, Y.P., Stashenko, P., 1992. Proinﬂammatory cytokines tumor necrosis factor-alpha
and IL-6, but not IL-1, down-regulate the osteocalcin gene promoter. J.
Immunol. 148, 788–794.
Lindsay, J.A., Moore, C.E., Day, N.P., Peacock, S.J., Witney, A.A., Stabler, R.A., Husain,
S.E., Butcher, P.D., Hinds, J., 2006. Microarrays reveal that each of the ten
dominant lineages of Staphylococcus aureus has a unique combination of
surface-associated and regulatory genes. J. Bacteriol. 188, 669–676.
Liu, Z.Q., Deng, G.M., Foster, S., Tarkowski, A., 2001. Staphylococcal peptidoglycans
induce arthritis. Arthritis Res. 3, 375–380.
Ljusberg, J., Wang, Y., Lang, P., Norgard, M., Dodds, R., Hultenby, K., Ek-Rylander, B.,
Andersson, G., 2005. Proteolytic excision of a repressive loop domain in
tartrate-resistant acid phosphatase by cathepsin K in osteoclasts. J. Biol. Chem.
280, 28370–28381.
Lomaga, M.A., Yeh, W.C., Sarosi, I., Duncan, G.S., Furlonger, C., Ho, A., Morony, S.,
Capparelli, C., Van, G., Kaufman, S., van der, H.A., Itie, A., Wakeham, A., Khoo,
W., Sasaki, T., Cao, Z., Penninger, J.M., Paige, C.J., Lacey, D.L., Dunstan, C.R., Boyle,
W.J., Goeddel, D.V., Mak, T.W., 1999. TRAF6 deﬁciency results in osteopetrosis
and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 13, 1015–1024.
Lynch, C.C., Hikosaka, A., Acuff, H.B., Martin, M.D., Kawai, N., Singh, R.K., Vargo-
Gogola, T.C., Begtrup, J.L., Peterson, T.E., Fingleton, B., Shirai, T., Matrisian, L.M.,
Futakuchi, M., 2005. MMP-7 promotes prostate cancer-induced osteolysis via
the solubilization of RANKL. Cancer Cell 7, 485–496.
Mackie, E.J., 2003. Osteoblasts: novel roles in orchestration of skeletal architecture.
Int. J. Biochem. Cell Biol. 35, 1301–1305.
Mahalingam, D., Szegezdi, E., Keane, M., Jong, S., Samali, A., 2009. TRAIL receptor
signalling and modulation: Are we on the right TRAIL?. Cancer Treat. Rev. 35,
280–288.
Mariathasan, S., Weiss, D.S., Newton, K., McBride, J., O’Rourke, K., Roose-Girma, M.,
Lee, W.P., Weinrauch, Y., Monack, D.M., Dixit, V.M., 2006. Cryopyrin activates
the inﬂammasome in response to toxins and ATP. Nature 440, 228–232.
Marriott, I., Hughes Jr., F.M., Bost, K.L., 2002. Bacterial infection of osteoblasts
induces interleukin-1beta and interleukin-18 transcription but not protein
synthesis. J. Interferon Cytokine Res. 22, 1049–1055.
Matsuo, K., Irie, N., 2008. Osteoclast–osteoblast communication. Arch. Biochem.
Biophys. 473, 201–209.
McCall, S.H., Sahraei, M., Young, A.B., Worley, C.S., Duncan, J.A., Ting, J.P., Marriott,
I., 2008. Osteoblasts express NLRP3, a nucleotide-binding domain and leucine-
rich repeat region containing receptor implicated in bacterially induced cell
death. J. Bone Miner. Res. 23, 30–40.
Meghji, S., Crean, S.J., Nair, S., Wilson, M., Poole, S., Harris, M., Henderson, B., 1997.
Staphylococcus epidermidis produces a cell-associated proteinaceous fraction
which causes bone resorption by a prostanoid-independent mechanism:relevance to the treatment of infected orthopaedic implants. Br. J. Rheumatol.
36, 957–963.
Meghji, S., Crean, S.J., Hill, P.A., Sheikh, M., Nair, S.P., Heron, K., Henderson, B.,
Mawer, E.B., Harris, M., 1998. Surface-associated protein from Staphylococcus
aureus stimulates osteoclastogenesis: possible role in S. aureus-induced bone
pathology. Br. J. Rheumatol. 37, 1095–1101.
Miao, E.A., Puche-Aranda, C.M., Dors, M., Clark, A.E., Bader, M.W., Miller, S.I.,
Aderem, A., 2006. Cytoplasmic ﬂagellin activates caspase-1 and secretion of
interleukin 1[beta] via Ipaf. Nat. Immunol. 7, 569–575.
Mitchell, G., Lamontagne, C.A., Brouillette, E., Grondin, G., Talbot, B.G., Grandbois,
M., Malouin, F., 2008. Staphylococcus aureus SigB activity promotes a strong
ﬁbronectin-bacterium interaction which may sustain host tissue colonization
by small-colony variants isolated from cystic ﬁbrosis patients. Mol. Microbiol.
70, 1540–1555.
Moisan, H., Brouillette, E., Jacob, C.L., Langlois-Begin, P., Michaud, S., Malouin, F.,
2006. Transcription of virulence factors in Staphylococcus aureus small-colony
variants isolated from cystic ﬁbrosis patients is inﬂuenced by SigB. J. Bacteriol.
188, 64–76.
Mundy, G.R., 1991. Inﬂammatory mediators and the destruction of bone. J.
Periodontal Res. 26, 213–217.
Murdoch, D.R., Everts, R.J., Chambers, S.T., Cowan, I.A., 1996. Vertebral osteomye-
litis due to Staphylococcus lugdunensis. J. Clin. Microbiol. 34, 993–994.
Musher, D.M., Baughn, R.E., Templeton, G.B., Minuth, J.N., 1977. Emergence of
variant forms of Staphylococcus aureus after exposure to gentamicin and
infectivity of the variants in experimental animals. J. Infect. Dis. 136, 360–369.
Nade, S., 2003. Septic arthritis. Best. Pract. Res. Clin. Rheumatol. 17, 183–200.
Nair, S., Song, Y., Meghji, S., Reddi, K., Harris, M., Ross, A., Poole, S., Wilson, M.,
Henderson, B., 1995. Surface-associated proteins from Staphylococcus aureus
demonstrate potent bone resorbing activity. J. Bone Miner. Res. 10, 726–734.
Nair, S.P., Meghji, S., Wilson, M., Nugent, I., Ross, A., Ismael, A., Bhudia, N.K., Harris,
M., Henderson, B., 1997. Clinical isolates of Staphylococcus aureus have
osteolytic surface proteins and a proportion of the population have antibodies
that block this activity: is this of prognostic signiﬁcance?. Br. J. Rheumatol. 36,
328–332.
Nair, S.P., Bischoff, M., Senn, M.M., Berger-Bachi, B., 2003. The sigma B regulon
inﬂuences internalization of Staphylococcus aureus by osteoblasts. Infect.
Immun. 71, 4167–4170.
Nanes, M.S., 2003. Tumor necrosis factor-alpha: molecular and cellular mecha-
nisms in skeletal pathology. Gene 321, 1–15.
Nanes, M.S., McKoy, W.M., Marx, S.J., 1989. Inhibitory effects of tumor necrosis
factor-alpha and interferon-gamma on deoxyribonucleic acid and collagen
synthesis by rat osteosarcoma cells (ROS 17/2.8). Endocrinology 124, 339–345.
Nanes, M.S., Rubin, J., Titus, L., Hendy, G.N., Catherwood, B., 1991. Tumor necrosis
factor-alpha inhibits 1,25-dihydroxyvitamin D3-stimulated bone Gla protein
synthesis in rat osteosarcoma cells (ROS 17/2.8) by a pretranslational
mechanism. Endocrinology 128, 2577–2582.
Naugler, W.E., Karin, M., 2008. The wolf in sheep’s clothing: the role of interleukin-
6 in immunity, inﬂammation and cancer. Trends Mol. Med. 14, 109–119.
Nesbitt, S.A., Horton, M.A., 1997. Trafﬁcking of matrix collagens through bone-
resorbing osteoclasts. Science 276, 266–269.
Nilsson, I.M., Lee, J.C., Bremell, T., Ryden, C., Tarkowski, A., 1997. The role of
staphylococcal polysaccharide microcapsule expression in septicemia and
septic arthritis. Infect. Immun. 65, 4216–4221.
Nilsson, I.M., Patti, J.M., Bremell, T., Hook, M., Tarkowski, A., 1998. Vaccination with
a recombinant fragment of collagen adhesin provides protection against
Staphylococcus aureus-mediated septic death. J. Clin. Invest. 101, 2640–2649.
Nilsson, I.M., Hartford, O., Foster, T., Tarkowski, A., 1999. Alpha-toxin and gamma-
toxin jointly promote Staphylococcus aureus virulence in murine septic
arthritis. Infect. Immun. 67, 1045–1049.
Osiri, M., Ruxrungtham, K., Nookhai, S., Ohmoto, Y., Deesomchok, U., 1998. IL-1beta,
IL-6 and TNF-alpha in synovial ﬂuid of patients with non-gonococcal septic
arthritis. Asian Pac. J. Allergy Immunol. 16, 155–160.
Palmqvist, N., Foster, T., Tarkowski, A., Josefsson, E., 2002. Protein A is a virulence
factor in Staphylococcus aureus arthritis and septic death. Microb. Pathog. 33,
239–249.
Palmqvist, N., Patti, J.M., Tarkowski, A., Josefsson, E., 2004. Expression of
staphylococcal clumping factor A impedes macrophage phagocytosis. Microbes
Infect. 6, 188–195.
Palmqvist, N., Foster, T., Fitzgerald, J.R., Josefsson, E., Tarkowski, A., 2005.
Fibronectin-binding proteins and ﬁbrinogen-binding clumping factors play
distinct roles in staphylococcal arthritis and systemic inﬂammation. J. Infect.
Dis. 191, 791–798.
Patti, J.M., Bremell, T., Krajewska-Pietrasik, D., Abdelnour, A., Tarkowski, A., Ryden,
C., Hook, M., 1994. The Staphylococcus aureus collagen adhesin is a virulence
determinant in experimental septic arthritis. Infect. Immun. 62, 152–161.
Peacock, S.J., Day, N.P., Thomas, M.G., Berendt, A.R., Foster, T.J., 2000. Clinical
isolates of Staphylococcus aureus exhibit diversity in fnb genes and adhesion to
human ﬁbronectin. J. Infect. 41, 23–31.
Peacock, S.J., Moore, C.E., Justice, A., Kantzanou, M., Story, L., Mackie, K., O’Neill, G.,
Day, N.P., 2002. Virulent combinations of adhesin and toxin genes in natural
populations of Staphylococcus aureus. Infect. Immun. 70, 4987–4996.
Peschel, A., Jack, R.W., Otto, M., Collins, L.V., Staubitz, P., Nicholson, G., Kalbacher,
H., Nieuwenhuizen, W.F., Jung, G., Tarkowski, A., van Kessel, K.P., van Strijp, J.A.,
2001. Staphylococcus aureus resistance to human defensins and evasion of
neutrophil killing via the novel virulence factor MprF is based on modiﬁcation
of membrane lipids with L-lysine. J. Exp. Med. 193, 1067–1076.
ARTICLE IN PRESS
J.A. Wright, S.P. Nair / International Journal of Medical Microbiology 300 (2010) 193–204204Pfeilschifter, J., Chenu, C., Bird, A., Mundy, G.R., Roodman, G.D., 1989. Interleukin-1
and tumor necrosis factor stimulate the formation of human osteoclast-like
cells in vitro. J. Bone Miner. Res. 4, 113–118.
Pivirotto, L.A., Cissel, D.S., Keeting, P.E., 1995. Sex hormones mediate interleukin-1
beta production by human osteoblastic HOBIT cells. Mol. Cell. Endocrinol. 111,
67–74.
Proctor, R.A., van, L.P., Kristjansson, M., Maslow, J.N., Arbeit, R.D., 1995. Persistent
and relapsing infections associated with small-colony variants of Staphylo-
coccus aureus. Clin. Infect. Dis. 20, 95–102.
Proctor, R.A., von Eiff, C., Kahl, B.C., Becker, K., McNamara, P., Herrmann, M., Peters,
G., 2006. Small colony variants: a pathogenic form of bacteria that facilitates
persistent and recurrent infections. Nat. Rev. Microbiol. 4, 295–305.
Reilly, S.S., Hudson, M.C., Kellam, J.F., Ramp, W.K., 2000. In vivo internalization of
Staphylococcus aureus by embryonic chick osteoblasts. Bone 26, 63–70.
Reott Jr., M.A., Ritchie-Miller, S.L., Anguita, J., Hudson, M.C., 2008. TRAIL expression
is induced in both osteoblasts containing intracellular Staphylococcus aureus
and uninfected osteoblasts in infected cultures. FEMS Microbiol. Lett. 278,
185–192.
Robinson, L.J., Borysenko, C.W., Blair, H.C., 2007. Tumor necrosis factor family
receptors regulating bone turnover: new observations in osteoblastic and
osteoclastic cell lines. Ann. NY Acad. Sci. 1116, 432–443.
Rodig, S.J., Meraz, M.A., White, J.M., Lampe, P.A., Riley, J.K., Arthur, C.D., King, K.L.,
Sheehan, K.C., Yin, L., Pennica, D., Johnson Jr., E.M., Schreiber, R.D., 1998.
Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles
of the Jaks in cytokine-induced biologic responses. Cell 93, 373–383.
Ryan, M.J., Kavanagh, R., Wall, P.G., Hazleman, B.L., 1997. Bacterial joint infections
in England and Wales: analysis of bacterial isolates over a four year period. Br.
J. Rheumatol. 36, 370–373.
Saez-Llorens, X., Mustafa, M.M., Ramilo, O., Fink, C., Beutler, B., Nelson, J.D., 1990.
Tumor necrosis factor alpha and interleukin 1 beta in synovial ﬂuid of infants
and children with suppurative arthritis. Am. J. Dis. Child. 144, 353–356.
Salo, J., Lehenkari, P., Mulari, M., Metsikko, K., Vaananen, H.K., 1997. Removal of
osteoclast bone resorption products by transcytosis. Science 276, 270–273.
Sdougkos, G., Chini, V., Papanastasiou, D.A., Christodoulou, G., Tagaris, G.,
Dimitracopoulos, G., Spiliopoulou, I., 2007. Methicillin-resistant Staphylococcus
aureus producing Panton–Valentine leukocidin as a cause of acute osteomye-
litis in children. Clin. Microbiol. Infect. 13, 651–654.
Seifert, H., Oltmanns, D., Becker, K., Wisplinghoff, H., von, E.C., 2005. Staphylococcus
lugdunensis pacemaker-related infection. Emerg. Infect. Dis. 11, 1283–1286.
Sendi, P., Proctor, R.A., 2009. Staphylococcus aureus as an intracellular pathogen: the
role of small colony variants. Trends Microbiol. 17, 54–58.
Sendi, P., Rohrbach, M., Graber, P., Frei, R., Ochsner, P.E., Zimmerli, W., 2006.
Staphylococcus aureus small colony variants in prosthetic joint infection. Clin.
Infect. Dis. 43, 961–967.
Shaw, L.N., Lindholm, C., Prajsnar, T.K., Miller, H.K., Brown, M.C., Golonka, E.,
Stewart, G.C., Tarkowski, A., Potempa, J., 2008. Identiﬁcation and characteriza-
tion of sigma, a novel component of the Staphylococcus aureus stress and
virulence responses. PLoS One 3, e3844.
Shirtliff, M.E., Mader, J.T., 2002. Acute septic arthritis. Clin. Microbiol. Rev. 15, 527–
544.
Sinha, B., Francois, P.P., Nusse, O., Foti, M., Hartford, O.M., Vaudaux, P., Foster, T.J.,
Lew, D.P., Herrmann, M., Krause, K.H., 1999. Fibronectin-binding protein acts as
Staphylococcus aureus invasin via ﬁbronectin bridging to integrin alpha5beta1.
Cell. Microbiol. 1, 101–117.
Smith, D.D., Gowen, M., Mundy, G.R., 1987. Effects of interferon-gamma and other
cytokines on collagen synthesis in fetal rat bone cultures. Endocrinology 120,
2494–2499.
Stapleton, M.R., Horsburgh, M.J., Hayhurst, E.J., Wright, L., Jonsson, I.M., Tarkowski,
A., Kokai-Kun, J.F., Mond, J.J., Foster, S.J., 2007. Characterization of IsaA and
SceD, two putative lytic transglycosylases of Staphylococcus aureus. J. Bacteriol.
189, 7316–7325.
Stoodley, P., Nistico, L., Johnson, S., Lasko, L.A., Baratz, M., Gahlot, V., Ehrlich, G.D.,
Kathju, S., 2008. Direct demonstration of viable Staphylococcus aureus bioﬁlms
in an infected total joint arthroplasty. A case report. J. Bone Joint Surg. Am. 90,
1751–1758.
Stott, N.S., 2001. Paediatric bone and joint infection. J. Orthop. Surg. (Hong Kong) 9,
83–90.
Takeuchi, O., Hoshino, K., Kawai, T., Sanjo, H., Takada, H., Ogawa, T., Takeda, K.,
Akira, S., 1999. Differential roles of TLR2 and TLR4 in recognition of gram-
negative and gram-positive bacterial cell wall components. Immunity 11,
443–451.
Takeuchi, O., Hoshino, K., Akira, S., 2000. Cutting edge: TLR2-deﬁcient and MyD88-
deﬁcient mice are highly susceptible to Staphylococcus aureus infection.
J. Immunol. 165, 5392–5396.
Tarkowski, A., Collins, L.V., Gjertsson, I., Hultgren, O.H., Jonsson, I.M., Sakiniene, E.,
Verdrengh, M., 2001. Model systems: modeling human staphylococcal arthritis
and sepsis in the mouse. Trends Microbiol. 9, 321–326.
Taubman, M.A., Kawai, T., 2001. Involvement of T-lymphocytes in periodontal
disease and in direct and indirect induction of bone resorption. Crit. Rev. Oral
Biol. Med. 12, 125–135.
Thomson, B.M., Mundy, G.R., Chambers, T.J., 1987. Tumor necrosis factors alpha and
beta induce osteoblastic cells to stimulate osteoclastic bone resorption.
J. Immunol. 138, 775–779.
Ting, J.P.Y., Willingham, S.B., Bergstralh, D.T., 2008. NLRs at the intersection of cell
death and immunity. Nat. Rev. Immunol. 8, 372–379.Tokukoda, Y., Takata, S., Kaji, H., Kitazawa, R., Sugimoto, T., Chihara, K., 2001.
Interleukin-1beta stimulates transendothelial mobilization of human periph-
eral blood mononuclear cells with a potential to differentiate into osteoclasts
in the presence of osteoblasts. Endocr. J. 48, 443–452.
Tsezou, A., Poultsides, L., Kostopoulou, F., Zintzaras, E., Satra, M., Kitsiou-Tzeli, S.,
Malizos, K.N., 2008. Inﬂuence of interleukin 1alpha (IL-1alpha), IL-4, and IL-6
polymorphisms on genetic susceptibility to chronic osteomyelitis. Clin.
Vaccine Immunol. 15, 1888–1890.
Tucker, K.A., Reilly, S.S., Leslie, C.S., Hudson, M.C., 2000. Intracellular Staphylococcus
aureus induces apoptosis in mouse osteoblasts. FEMS Microbiol. Lett. 186,
151–156.
U.K. Health Protection Agency, 2008. Surgical Site Infection – National aggregated
data on Surgical Site Infections for hospitals that have participated in Surgical
Site Infection Surveillance Scheme (SSISS) between October 1997 and
December 2005. /http://www.hpa.org.uk/HPA/Topics/InfectiousDiseases/In
fectionsAZ/1202115536296/S.
Udagawa, N., Takahashi, N., Katagiri, T., Tamura, T., Wada, S., Findlay, D.M., Martin,
T.J., Hirota, H., Taga, T., Kishimoto, T., Suda, T., 1995. Interleukin (IL)-6 induction
of osteoclast differentiation depends on IL-6 receptors expressed on osteo-
blastic cells but not on osteoclast progenitors. J. Exp. Med. 182, 1461–1468.
Vaananen, H.K., Laitala-Leinonen, T., 2008. Osteoclast lineage and function. Arch.
Biochem. Biophys. 473, 132–138.
Vallianou, N., Evangelopoulos, A., Makri, P., Zacharias, G., Stefanitsi, P., Karachalios,
A., Avgerinos, P.C., 2008. Vertebral osteomyelitis and native valve endocarditis
due to Staphylococcus simulans: a case report. J. Med. Case Reports 2, 183.
van de Lest, C.H., Vaandrager, A.B., 2007. Mechanism of cell-mediated mineraliza-
tion. Curr. Opin. Orthop. 18, 434–443.
Vaudaux, P., Francois, P., Bisognano, C., Kelley, W.L., Lew, D.P., Schrenzel, J., Proctor,
R.A., McNamara, P.J., Peters, G., von Eiff, C., 2002. Increased expression of
clumping factor and ﬁbronectin-binding proteins by hemB mutants of
Staphylococcus aureus expressing small colony variant phenotypes. Infect.
Immun. 70, 5428–5437.
Verstrepen, L., Bekaert, T., Chau, T.L., Tavernier, J., Chariot, A., Beyaert, R., 2008. TLR-
4, IL-1R and TNF-R signaling to NF-kappaB: variations on a common theme.
Cell. Mol. Life Sci. 65, 2964–2978.
von Eiff, C., 2008. Staphylococcus aureus small colony variants: a challenge to
microbiologists and clinicians. Int. J. Antimicrob. Agents 31, 507–510.
von Eiff, C., Bettin, D., Proctor, R.A., Rolauffs, B., Lindner, N., Winkelmann, W.,
Peters, G., 1997a. Recovery of small colony variants of Staphylococcus aureus
following gentamicin bead placement for osteomyelitis. Clin. Infect. Dis. 25,
1250–1251.
von Eiff, C., Heilmann, C., Proctor, R.A., Woltz, C., Peters, G., Gotz, F., 1997b. A site-
directed Staphylococcus aureus hemB mutant is a small-colony variant which
persists intracellularly. J. Bacteriol. 179, 4706–4712.
von Eiff, C., Vaudaux, P., Kahl, B.C., Lew, D., Emler, S., Schmidt, A., Peters, G., Proctor,
R.A., 1999. Bloodstream infections caused by small-colony variants of
coagulase-negative staphylococci following pacemaker implantation. Clin.
Infect. Dis. 29, 932–934.
von Eiff, C., Becker, K., Metze, D., Lubritz, G., Hockmann, J., Schwarz, T., Peters, G.,
2001. Intracellular persistence of Staphylococcus aureus small-colony variants
within keratinocytes: a cause for antibiotic treatment failure in a patient with
Darier’s disease. Clin. Infect. Dis. 32, 1643–1647.
von Eiff, C., Peters, G., Becker, K., 2006. The small colony variant (SCV) concept – the
role of staphylococcal SCVs in persistent infections. Injury 37 (Suppl. 2), S26–S33.
Wada, T., Nakashima, T., Hiroshi, N., Penninger, J.M., 2006. RANKL-RANK signaling
in osteoclastogenesis and bone disease. Trends Mol. Med. 12, 17–25.
Wajant, H., Pﬁzenmaier, K., Scheurich, P., 2003. Tumor necrosis factor signaling.
Cell Death Differ. 10, 45–65.
Wang, B., Yurecko, R.S., Dedhar, S., Cleary, P.P., 2006. Integrin-linked kinase is an
essential link between integrins and uptake of bacterial pathogens by
epithelial cells. Cell. Microbiol. 8, 257–266.
Weichert, S., Sharland, M., Clarke, N.M., Faust, S.N., 2008. Acute haematogenous
osteomyelitis in children: is there any evidence for how long we should treat?
Curr. Opin. Infect. Dis. 21, 258–262.
Xing, L., Carlson, L., Story, B., Tai, Z., Keng, P., Siebenlist, U., Boyce, B.F., 2003.
Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required
for IL-1-induced bone resorption. J. Bone Miner. Res. 18, 260–269.
Xu, Y., Rivas, J.M., Brown, E.L., Liang, X., Hook, M., 2004. Virulence potential of the
staphylococcal adhesin CNA in experimental arthritis is determined by its
afﬁnity for collagen. J. Infect. Dis. 189, 2323–2333.
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.,
Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T.,
Higashio, K., Udagawa, N., Takahashi, N., Suda, T., 1998. Osteoclast differentia-
tion factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor
and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95, 3597–3602.
Yoshii, T., Magara, S., Miyai, D., Nishimura, H., Kuroki, E., Furudoi, S., Komori, T.,
Ohbayashi, C., 2002. Local levels of interleukin-1beta, 4, -6 and tumor
necrosis factor alpha in an experimental model of murine osteomyelitis due to
Staphylococcus aureus. Cytokine 19, 59–65.
Zauli, G., Rimondi, E., Nicolin, V., Melloni, E., Celeghini, C., Secchiero, P., 2004. TNF-
related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation
induced by RANKL plus M-CSF. Blood 104, 2044–2050.
Zou, W., Hakim, I., Tschoep, K., Endres, S., Bar-Shavit, Z., 2001. Tumor necrosis
factor-alpha mediates RANK ligand stimulation of osteoclast differentiation by
an autocrine mechanism. J. Cell. Biochem. 83, 70–83.
